

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

BIOPHAN TECHNOLOGIES INC
Form 424B3
July 14, 2003

PROSPECTUS
BIOPHAN TECHNOLOGIES, INC.

18,991,222 SHARES OF COMMON STOCK

There are hereby offered up to 18,991,222 shares of the common stock, of Biophan Technologies, Inc. All of these shares are being offered by selling shareholders. Biophan will not receive any of the proceeds from the sale of shares by the selling shareholders.

This prospectus relates primarily to the resale by Spectrum Advisors, Ltd., of up to 8,960,000 shares of our common stock that may be issued through a common stock purchase agreement between us and Spectrum, as further described in this prospectus.

Spectrum is an "underwriter" within the meaning of the Securities Act of 1933 in connection with its sales.

This prospectus also relates to the resale of the following shares:

- * up to 448,000 shares of our common stock underlying up to 448,000 warrants to be issued to Carolina Financial Services, LLC for services rendered in relation to the common stock purchase agreement
- * 5,521,100 shares of common stock, and 2,760,550 shares of common stock underlying warrants, issued to certain purchasers in a private placement of our securities, pursuant to which the purchasers were granted the right to have their common stock registered in a subsequent registration statement
- * 121,572 common shares underlying warrants granted to principals of CFS for financial advisory and investment banking services;
- * 1,180,000 shares issuable upon exercise of warrants issued to Biomed Solutions, LLC; and

Our common stock trades on the over-the-counter market under the symbol "BIPH." The last reported sales price for our common stock on July 9, 2003 was \$.34 per share.

The Securities Offered Hereby Involve A High Degree Of Risk.

INVESTING IN OUR COMMON STOCK INVOLVES RISKS WHICH ARE DESCRIBED UNDER "RISK FACTORS" BEGINNING ON PAGE 5.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is accurate or complete. It is illegal for anyone to tell you otherwise.

The date of this prospectus is June 12, 2003.

1

TABLE OF CONTENTS

PART I

Page

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

Prospectus Summary	4
Summary Historical Financial Information	5
Risk Factors	6
Use of Proceeds	13
Nature of Trading Market	13
Dividend Policy	14
Capitalization	14
Plan of Operation	14
Business	17
Legal Proceedings	40
Management	40
Executive Compensation	46
Security Ownership of Certain Beneficial Owners and Management	48
Certain Transactions	51
Description of Securities	53
Shares Eligible for Resale	56
Restated Common Stock Purchase Agreement	57
Selling Stockholders	58
Plan of Distribution	64
Legal Matters	66
Experts	67
Where you can find Additional Information	67
Financial Statements	F-1
PART II	
Information not required in prospectus	68
Signatures	80

You should rely only on the information contained in this prospectus. We have not, and the underwriters have not, authorized anyone to provide you with different information. If anyone provides you with different information, you should not rely on it. We are not, and the underwriters are not, making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information contained in this

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

prospectus is accurate only as of the date on the front cover of this prospectus. Our business, financial condition, results of operations and prospects may have changed since that date.

3

PROSPECTUS SUMMARY

This summary is not complete and does not contain all of the information that you should consider before investing in our common stock. You should read the entire prospectus carefully, including the more detailed information regarding our company, the risks of purchasing our common stock discussed under "risk factors," and our financial statements and the accompanying notes.

Biophan Technologies, Inc.

Biophan is an early-stage research and development company focusing on technology that will enable certain medical procedures and biomedical devices, including cardiac pacemakers, to become safe and compatible with magnetic resonance imagining (MRI) diagnostics. Our approach is based on multiple technologies, some that are patented and others for which we have U.S. and foreign patents pending. Our research efforts are focusing on demonstrating the feasibility of our coating and filtering solutions which we intend to license to medical device manufacturers for use in their existing and future products. We incorporated on August 1, 1968 and began our current line of business on December 1, 2000. Through our fiscal year ended February 28, 2003, we have had no revenues from operations and have incurred cumulative net losses of \$7,973,157. To date, we have relied entirely on sales of our securities and loans to fund operations.

Common Stock Purchase Agreement Relating To Equity Line

Effective November 22, 2002, we entered into a restated common stock purchase agreement with Spectrum Advisors, Ltd. for the potential future issuance and sale of up to \$3,000,000 of our common stock. This agreement restated and superseded a common stock purchase agreement entered into with Bonanza Capital Masterfund, Ltd. as of June 6, 2002, on essentially the same terms and conditions. Pursuant to the common stock purchase agreement we, at our sole discretion and from time to time over a period of 24 months, may draw down on this facility, sometimes termed an equity line, and Spectrum is obligated to purchase shares of our common stock. The purchase price of the common stock purchased as to any draw down will be equal to 80% of the average daily volume weighted average price of our common stock for the five trading days preceding the applicable date. The minimum draw down which Spectrum is obligated to honor for any trading day is \$12,500. Under certain circumstances, we may increase Spectrum's obligation under the equity line to \$10,000,000. We are currently registering only 8,960,000 shares for sale under the equity line; at \$.34 the closing price of our common stock on July 9, 2003, we would only be able to draw down up to approximately \$2,437,000 on the equity line of credit. We anticipate that we will register additional shares in the future to enable us to take full advantage of the equity line.

The Offering

Securities offered by selling
shareholders..... Up to 18,991,222 shares of common stock,
representing:

* up to 8,960,000 shares issuable
pursuant to the equity line

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

* up to 448,000 shares issuable upon exercise of warrants to be issued in connection with the equity line

Page 4

* 8,311,650 shares issued to investors in our recent private placement or upon exercise of warrants issued in connection with that offering, plus 258,006 shares issued to a finder in connection with that offering;

*121,572 shares issuable upon exercise of warrants issued to our financial advisors;

* 1,180,000 shares issuable upon exercise of warrants issued to Biomed Solutions, LLC;

Use of Proceeds..... We will not receive any proceeds from the sale of shares by selling shareholders.

Risk Factors..... An investment in our common stock involves a high degree of risk and could result in a loss of your entire investment.

OTC symbol..... BIPH

Executive Offices

Our executive offices are located at 150 Lucius Gordon Drive, Suite 215, West Henrietta, New York 14586. Our telephone number is (585) 214-2441 and our website is: www.biophan.com.

SUMMARY HISTORICAL FINANCIAL INFORMATION

The following table presents summarized financial information as of the fiscal years ended February 28, 2003, 2002 and 2001. The information is extracted from the consolidated financial statements presented elsewhere in this prospectus and in previous filings and should be read in conjunction therewith.

Operating Data:	Year ended February 28, 2003	Year ended February 28, 2002	Year ended February 28, 2001
Revenue	-0-	-0-	-0-
Salaries and related	\$ 648,304	\$ 461,629	\$ 59,861
General & administrative expenses	582,174	475,520	16,059

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

Total expenses	(3,438,252)	3,705,917	729,130
Net (loss)	(3,438,252)	(3,705,917)	(729,130)
Net loss per share	(0.11)	(0.14)	(0.08)
Weighted average shares outstanding	31,731,051	27,000,962	9,166,887

Page	5		
Balance Sheet Data:	February 28, 2003	February 28, 2002	February 28, 2001
Current assets	\$ 476,353	\$ 672,823	\$ 172,092
Total assets	683,056	866,638	343,752
Current liabilities	796,187	645,389	280,992
Long-term liabilities	83,333	-0-	438,000
Stockholders' equity (deficiency)	(196,464)	221,249	(375,240)
Working capital	(319,834)	27,434	(108,900)

RISK FACTORS

Please consider the following risk factors together with the other information presented in this prospectus including the financial statements and the notes thereto before investing in our common stock. The trading price of our common stock could decline due to any of the following risks, and you might lose all or part of your investment.

We Are a New Business with a Limited Operating History and No Revenues to Date and Are Not Likely to Succeed Unless We Can Overcome the Many Obstacles We Face.

We are a development-stage company with limited prior business operations and no revenues. We are presently engaged in the early stage development of certain medical procedures and biomedical devices. Unless we are able to secure adequate funding, we may not be able to successfully develop and market our products and our business will most likely fail. Because of our limited operating history, you may not have adequate information on which you can base an evaluation of our business and prospects. To date, our efforts have been allocated primarily to the following:

- * organizational activities;
- * developing a business plan;
- * obtaining interim funding;
- * conducting research and working toward the ultimate successful development of our products; and
- * marketing to major biomedical manufacturers.

In order to establish ourselves in the medical device market, we are dependent upon continued funding and the successful development and marketing

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

of our products. You should be aware of the increased risks, uncertainties, difficulties and expenses we face as a research and development company and that an investment in our common stock may be worthless if our business fails.

We Have Generated No Revenues and If We Are Unable to Generate Sufficient Revenues in the Future, We May Not Be Able to Continue Our Business.

We are still in our formative and development stage. As an investor, you should be aware of the difficulties, delays and expenses normally encountered by an enterprise in its development stage, many of which are beyond our control, including unanticipated research and developmental expenses, employment costs, and administrative expenses. We cannot assure our investors that our proposed business plans as described in this prospectus will materialize or prove successful, or that we will ever be able to finalize development of our products or operate profitably. If we cannot operate profitably, you could lose your entire investment. As a result of the start-up

Page

6

nature of our business, initially we expect to sustain substantial operating expenses without generating significant revenues.

We Have a History of Losses and a Large Accumulated Deficit and We Expect Future Losses That May Cause Our Stock Price to Decline.

For the fiscal years ended February 28, 2003, 2002 and 2001, we incurred net losses of \$3,438,252, \$3,705,917 and \$729,130, respectively. We expect to lose more money as we spend additional capital to develop and market our technologies and establish our infrastructure and organization to support anticipated operations. We cannot be certain whether we will ever earn a significant amount of revenues or profit, or, if we do, that we will be able to continue earning such revenues or profit. Also, the current economic weakness may limit our ability to develop and ultimately market our technologies. Any of these factors could cause our stock price to decline and result in you losing a portion or all of your investment.

Our Inability to Retain and Attract Key Personnel Could Adversely Affect our Business.

We believe that our future success will depend on the abilities and continued service of certain of our senior management and executive officers, particularly our president and CEO and those persons involved in the research and development of our products. If we are unable to retain the services of these persons, or if we are unable to attract additional qualified employees, researchers and consultants, we may be unable to successfully finalize and eventually market our medical devices and other products being developed, which will have a material adverse effect on our business.

Our Research and Development Efforts May Not Result in Commercially Viable Products Which Could Result in a Decline of Our Stock Price and a Loss of Your Investment.

Our technologies are in the development stage. Further research and development efforts will be required to develop these technologies to the point where they can be incorporated into commercially viable or salable products. We have set forth in this prospectus our proposed research and development program as it is currently conceived. We cannot assure you, however, that this program will be accomplished in the order or in the time frame set forth. We reserve the right to modify the research and development program. We may not succeed in developing commercially viable products from our technologies. If not, our ability to generate revenues from our

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

technologies will be severely limited. This would result in the loss of all or part of your investment.

We May Not Have Opportunities To Enter Into Strategic Partnerships for the Commercialization of our Technologies Which Could Have a Severe Negative Impact on Our Ability to Market Our Products.

We intend to enter into strategic partnerships or other relationships with established biomedical, pharmaceutical and bio-pharmaceutical companies to obtain the necessary regulatory approvals and to undertake the manufacturing and marketing efforts required to commercialize our products. However, we do not have commitments at this time from any potential partners. If we are unable to enter into any new partnerships, then we may be unable to commence the commercialization of our products.

We May Not Be Able To Develop A Market For Our Technology Which Will Most Likely Cause Our Stock Price to Decline.

Page

7

The demand and price for our technology and related products will be based upon the existence of markets for the technology and products and the markets for products of others, which may utilize our technology. The extent to which we may gain a share of our intended markets will depend, in part, upon the cost effectiveness and performance of our technology and products when compared to alternative technologies, which may be conventional or heretofore unknown. If the technology or products of other companies provide more cost-effective alternatives or otherwise outperform our technology or products, the demand for our technology or products maybe adversely affected. Our success will be dependent upon market acceptance of our technology and related products. Failure of our technology to achieve and maintain meaningful levels of market acceptance would materially and adversely affect our business, financial condition, results of operations and market penetration. This would likely cause our stock price to decline.

If We Are Not Able to Compete Effectively in the Competitive Medical Device Industry, Our Future Growth and Operating Results Will Suffer.

Our future success depends on our ability to compete effectively with other manufacturers of medical devices, including major manufacturers of pacemakers and other implantable devices that may have internal development programs. We are an early-stage research and development company engaged exclusively in developing our initial products. We have not yet completed our first product and have no revenue from operations. As a result, we may have difficulty competing with larger, established medical device companies. Most of our potential competitors will be established, well-known companies that have:

- * substantially greater financial, technical and marketing resources;
- * larger customer bases;
- * better name recognition;
- * related product offerings; and
- * larger marketing areas.

Companies such as Medtronic Incorporated, Guidant Corporation, St. Jude Medical, Boston Scientific and Johnson & Johnson are major, international providers of active medical devices currently contraindicated for MRI. Because these companies may possibly develop MRI safe solutions for their own product lines, they may ultimately be in competition with us. These companies represent a wide array of medical devices and products, technologies and approaches. Most of these companies have more resources

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

than we do and, therefore, a greater opportunity to develop comparable products and bring those products to market more efficiently than us. If we do not compete effectively with current and future competitors, our future growth and operating results will be adversely affected.

We May Not Be Able To Obtain Necessary Government Approval To Market Our Technology Which Will Most Likely Cause Our Stock Price to Decline and Our Business to Fail.

Our marketing partners must obtain the approval of the U.S. Food and Drug Administration in order to market our MRI-safe technology. If these approvals are not obtained, or are significantly delayed, our ability to generate revenues may be adversely affected and our development and marketing efforts inhibited. This would most likely cause our stock price to decline and result in the loss of all or part of your investment.

We May Not Be Able To Protect Our Proprietary Rights and We May Infringe the Proprietary Rights of Others. Our Inability to Protect Our Rights Could Impair Our Business and Cause us to Incur Substantial Expense to Enforce our Rights.

Page

8

Proprietary rights are critically important to us. Although we have exclusive licenses to three issued U.S. patents for MRI safety-related technology and we intend to aggressively pursue additional patent protection for our technologies as we continue to develop them, we cannot assure you that any additional patents will be issued. Although we will seek to defend our patents and to protect our other proprietary rights, our actions may be inadequate to protect our patents and other proprietary rights from infringement by others, or to prevent others from claiming infringement of their patents and other proprietary rights.

Policing unauthorized use of our technology is difficult and some foreign laws do not provide the same level of protection as U.S. laws. Litigation may be necessary in the future to enforce our intellectual property rights, to protect our trade secrets or patents that we may obtain, or to determine the validity and scope of the proprietary rights of others. Such litigation could result in substantial costs and diversion of resources and have a material adverse effect on our future operating results.

Because Two Of Our Directors Are Equity Owners And Managers Of Biomed Solutions, LLC, A Creditor And Shareholder Of Biophan, There May Be Conflicts Of Interest.

Michael L. Weiner, our President, CEO and director, is the Manager and a 24.3% beneficial equity member of Biomed. Mr. Weiner, and Ross Kenzie, also a director of Biophan, make up the Biomed Board of Members. Biomed and its members own a significant amount of our outstanding common stock and we owe Biomed \$500,000 plus interest for the transfer to us of its MRI-compatible pacemaker patents pending. We have also executed a line of credit with Biomed pursuant to which we owe Biomed \$166,050 plus accrued interest as of the date hereof. We have issued to Biomed 1,180,000 warrants for the purchase of our common stock. Mr. Weiner is also the Manager and 42.3% equity member of Technology Innovations, LLC, which is a 57% equity member of Biomed. Further, Mr. Weiner is on the board of Nanoset, LLC, an entity owned in part by Biomed and with which we have negotiated a technology license agreement and are exploring acquiring additional rights to Nanoset's technology.

Because of their relationships with these other entities, Messrs. Weiner and Kenzie may have conflicts of interest with respect to certain matters

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

affecting us. Biomed is a creditor of Biophan and has the right to reacquire the MRI-compatible technology that it sold to us if payments are not made on a timely basis. Thus, a potential conflict could arise as to the enforcement of Biomed's rights to the MRI-compatible technology under its agreement with us. Also, a conflict could arise among the entities in the determination of which entity might acquire a particular technology. All potential conflicts may not be resolved in a manner that is favorable to us. We believe it is impossible to predict the precise circumstances under which future potential conflicts may arise and therefore intend to address potential conflicts on a case-by-case basis. Under Nevada law, directors have a fiduciary duty to act in good faith and with a view to the interests of the corporation.

If We Fail To Pay The Purchase Price For Our Technology, That Technology Will Revert To Biomed, Which Will Significantly And Negatively Impact Our Business And Your Investment.

Under the Transfer Agreement with Biomed in connection with our acquisition of the MRI intellectual property rights, Biomed maintains a

Page

9

security interest in the underlying patents until the amount of \$500,000, plus interest at 8% per annum, is paid to Biomed. Biomed has the right to take back these intellectual property rights if we do not satisfy the liability which is payable in 12 equal installments commencing June 1, 2004. In the event we are unable to satisfy this condition, and we lose our rights to the technology, we will suffer significant harm to our business and financial condition which would most likely cause the price of our stock to decline.

The So Called "Penny Stock Rule" Could Make It Cumbersome For Brokers And Dealers To Trade In Our Common Stock, Making The Market For Our Common Stock Less Liquid Which Could Cause The Price Of Our Stock To Decline.

Trading of our common stock on the OTC Bulletin Board may be subject to certain provisions of the Securities Exchange Act of 1934, commonly referred to as the "penny stock" rule. A penny stock is generally defined to be any equity security that has a market price less than \$5.00 per share, subject to certain exceptions. If our stock is deemed to be a penny stock, trading in our stock will be subject to additional sales practice requirements on broker-dealers. These may require a broker dealer to:

- * make a special suitability determination for purchasers of our shares;
- * receive the purchaser's written consent to the transaction prior to the purchase; and
- * deliver to a prospective purchaser of our stock, prior to the first transaction, a risk disclosure document relating to the penny stock market.

Consequently, penny stock rules may restrict the ability of broker-dealers to trade and/or maintain a market in our common stock. Also, prospective investors may not want to get involved with the additional administrative requirements, which may have a material adverse effect on the trading of our shares.

Risks Related To The Equity Line

The Equity Line May Not Generate Sufficient Funds For Our Needs. Additional Required Capital May Not Be Available At Attractive Terms Which Would Have A Material Negative Effect On Our Operating Results And Our Stock Price.

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

The funds that we raise by drawing upon the equity line may not be sufficient to carry out all of the plans described in this prospectus or to achieve financial success. We do not have commitments for additional financing. To secure additional financing, we may have to borrow money or sell more securities, which may reduce the value of the securities to be issued as a result of this offering. We may be unable to secure additional financing on favorable terms.

Selling additional stock, either privately or publicly, could dilute the equity interests of our stockholders. If we borrow more money, we will have to pay interest and may also have to agree to restrictions that limit our operating flexibility. If we are unable to obtain adequate financing, we may have to curtail business operations which would have a material negative effect on operating results and most likely result in a lower stock price.

The Common Stock Purchase Agreement Limits The Number Of Shares Of Common Stock Spectrum Is Permitted To Hold At Any One Time To 9.9%, Which May Further Limit Our Ability To Draw Down Amounts That We Request.

Page

10

The common stock purchase agreement provides that we may not sell shares of our common stock pursuant to our draw down right under such agreement if sale would cause Spectrum to beneficially own more than 9.9% of our issued and outstanding common stock at any one time. As of the date hereof, 9.9% of our outstanding common stock would be 4,274,614 shares. At a price of \$.34 per share, we would only be able to draw down approximately \$1,163,000 under the equity line. Accordingly, we may have to significantly curtail the scope of our operations and alter our business plan if, at the time of one or more draw downs, this 9.9% restriction results in our inability to draw down some or all of the amounts requested in any draw down notice. Of course, any resale of our common stock by Spectrum would reduce their beneficial ownership, reducing the effect of the 9.9% provision on our ability to exercise draw downs.

We Do Not Have A Sufficient Number Of Authorized But Unissued And Unreserved Shares To Permit Us To Take Full Advantage Of The Spectrum Equity Line Of Credit At Current Market Prices. If We Are Unable To Obtain Approval For An Increase In Our Authorized Shares, We Will Have To Curtail Our Development Efforts, And We May Be Unable To Achieve Our Business Plan.

Under the Spectrum equity line of credit, we are permitted to draw up to \$3,000,000 and, under certain circumstances, to increase this commitment up to \$10,000,000. To draw down \$3,000,000 at our current market price would require us to issue approximately 10,000,0000 shares to Spectrum and approximately 500,000 warrants to CFS. We currently have available for issuance only 9,283,537 common shares, so we are registering 8,960,000 shares for issuance to Spectrum and 437,000 for issuance to CFS upon exercise of its warrants. At our current market price, this will only allow us to draw down approximately \$2,688,000. If our market price declines, we will be able to draw down even less.

Unless the market price of our common stock substantially increases, we must obtain approval from our shareholders to increase our authorized shares, and then file and have declared effective a new registration statement, in order to take full advantage of the equity line of credit. If we are unable to do so, we may have to curtail our technology development efforts, and our business and the price of our stock may be adversely affected.

Our Common Stock Purchase Agreement With Spectrum And The Issuance Of Shares

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

To Spectrum Thereunder May Cause Significant Dilution To Our Stockholders And May Have An Adverse Impact On The Market Price Of Our Common Stock.

The resale by Spectrum of our common stock that it purchases from us will increase the number of our publicly traded shares, which could depress the market price of our common stock. Moreover, as all the shares we sell to Spectrum will be available for immediate resale, the mere prospect of our sales to it could depress the market price for our common stock. If we were to require Spectrum to purchase our common stock at a time when our stock price is low, our existing common stockholders will experience substantial dilution. The issuance of shares to Spectrum will therefore dilute the equity interest of existing stockholders and could have an adverse effect on the market price of our common stock.

The perceived risk of dilution may cause our stockholders to sell their shares, which would contribute to a decline in the price of our common stock. Moreover, the perceived risk of dilution and the resulting downward pressure on our stock price could encourage investors to engage in short sales of our common stock. By increasing the number of shares offered for sale, material amounts of short selling could further contribute to progressive price

Page

11

declines in our common stock.

Our Common Stock Has Experienced In The Past, And Is Expected To Experience In The Future, Significant Price And Volume Volatility, Which Substantially Increases The Risk That You May Not Be Able To Sell Your Shares at or above the Price That You Pay for the Shares.

Because of the limited trading market for our common stock, and because of the possible price volatility, you may not be able to sell your shares of common stock when you desire to do so. During 2002, and through February 2003 our common stock was sold and purchased at prices that ranged from a high of \$6.45 to a low of \$0.18 per share. The inability to sell your shares in a rapidly declining market may substantially increase your risk of loss because of such illiquidity and because the price for our common stock may suffer greater declines because of its price volatility.

The price of our common stock that will prevail in the market after this offering may be higher or lower than the price you pay. Certain factors, some of which are beyond our control, that may cause our share price to fluctuate significantly include, but are not limited to, the following:

- * variations in our quarterly operating results;
- * our ability to complete the research and development of our technologies;
- * the development of a market in general for our products;
- * changes in market valuations of similar companies;
- * announcement by us or our competitors of significant contracts, acquisitions, strategic partnerships, joint ventures or capital commitments;
- * loss of a major customer or failure to complete significant transactions;
- * additions or departures of key personnel; and

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

* fluctuations in stock market price and volume.

Additionally, in recent years the stock market in general, and the OTC-BB and technology stocks in particular, have experienced extreme price and volume fluctuations. In some cases, these fluctuations are unrelated or disproportionate to the operating performance of the underlying company. These market and industry factors may materially and adversely affect our stock price, regardless of our operating performance.

In the past, class action litigation often has been brought against companies following periods of volatility in the market price of those companies' common stock. If we become involved in this type of litigation in the future, it could result in substantial costs and diversion of management attention and resources, which could have a further negative effect on your investment in our stock.

Because Spectrum Is A Resident Of A Foreign Country, It May Be Difficult Or Impossible To Obtain Or Enforce Judgments Against Spectrum.

Spectrum is a Nevis corporation with offices in London, England, and a

Page

12

substantial portion of its assets are located outside of the United States. As a result, it may be difficult or impossible to effect service of process on Spectrum within the United States. It may also be difficult or impossible to enforce judgments entered against Spectrum in courts in the United States based on civil liability provisions of the securities laws of the United States. In addition, judgments obtained in the United States, especially those awarding punitive damages, may not be enforceable in foreign countries.

Special Note Regarding Forward-Looking Statements

This prospectus contains forward-looking statements that involve risks and uncertainties. These include statements about our expectations, plans, objectives, assumptions or future events. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "estimate," "plans," "potential," "projects," "continuing," "ongoing," "expects," "management believes," "we believe," "we intend" and similar expressions. These statements involve estimates, assumptions and uncertainties that could cause actual results to differ materially from those expressed for the reasons described in this prospectus. You should not place undue reliance on these forward-looking statements.

You should be aware that our actual results could differ materially from those contained in the forward-looking statements due to a number of factors:

- * continued development of our technology
- * dependence on key personnel
- * competitive factors
- * the operation of our business
- * general economic conditions

The forward-looking statements speak only as of the date on which they are made, and, except to the extent required by federal securities laws, we undertake no obligation to update any forward-looking statement to reflect

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

USE OF PROCEEDS

We will not receive any of the proceeds from the sale of shares by any selling shareholder. Because we are not obligated to, and may decide not to, exercise any draw downs under the equity line of credit agreement, we may not receive any proceeds under the equity line. Further, no warrant holder is compelled to exercise their warrants, so we may not receive any proceeds from warrant exercise.

NATURE OF TRADING MARKET

Our common stock is listed on the OTC Bulletin Board under the symbol BIPH. The stock was not actively traded until October 2001 and the following table sets forth, for the fiscal quarters indicated, the high and low bid prices.

Page

13

These quotations reflect inter-dealer prices, without mark-up, mark-down or commission, and may not represent actual transactions.

Quarter Ended	High	Low
November 30, 2001	\$6.50	\$5.50
February 28, 2002	\$7.25	\$2.37
May 31, 2002	\$2.65	\$.75
August 31, 2002	\$1.13	\$.30
November 30, 2002	\$.38	\$.18
February 28, 2003	\$1.15	\$.29

We currently have outstanding 38,903,314 shares held by approximately 400 shareholders.

DIVIDEND POLICY

We have never paid cash dividends and have no plans to do so in the foreseeable future. Our future dividend policy will be determined by our Board of Directors and will depend upon a number of factors, including our financial condition and performance, our cash needs and expansion plans, income tax consequences, and the restrictions that applicable laws and our credit arrangements then impose.

CAPITALIZATION

The following table sets forth our capitalization as of February 28, 2003.

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

You should read this information in conjunction with our financial statements and the accompanying notes, and the other financial information appearing elsewhere in this prospectus.

Long-term debt:	\$ 83,333
	=====
Stockholders' equity(deficiency):	
Common stock, \$.005 par value	
Authorized, 60,000,000 shares	
Issued and outstanding:	
37,634,693 shares	\$ 188,173
Additional paid-in capital	7,588,520
Accumulated deficit	(7,973,157)

	\$ (196,464)
	=====

PLAN OF OPERATION

We are currently in the development stage of operations and expect to be

Page

14

in that mode for the foreseeable future. Our primary mission is to develop and commercially exploit technologies for enabling cardiac pacemakers and other life sustaining medical devices to be safe and compatible with magnetic resonance imaging (MRI) and other equipment that generates powerful magnetic and radio frequency signals.

We will receive no proceeds from the sale of our common stock by the selling stockholders pursuant to this prospectus. However, we will receive proceeds only from draw-downs under the equity line of credit. We estimate that proceeds from potential sales of our stock to Spectrum Advisors under the equity line of approximately \$2,437,000 will be sufficient to satisfy our cash requirements over the ensuing twelve months. If we are limited to the condition that Spectrum may not own more that 9.9% of the outstanding shares at any one time, we would be able to draw down only approximately \$1,163,000 under the equity line. Accordingly, we would have to curtail some of our programs, reduce our expenses and renegotiate loans based on the available funds. Our estimate of the use of proceeds given each situation is as follows:

	Proceeds from Spectrum	9.9% Limitation
	-----	-----
Research and product development	\$ 970,000	\$ 526,000
Operating expenses, including		
administrative salaries and benefits,		
office expenses, rent expense, legal		
and accounting, publicity, investor		
relations	858,300	295,700
Repay related party loans plus interest	290,000	150,000
Commission on draw downs under equity line		
of credit	243,700	116,300
Costs of registration	75,000	75,000
	-----	-----
	\$2, 437,000	\$1, 163,000
	=====	=====

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

The above table takes into consideration the cost of filing the registration statement, of which this prospectus is a part, and includes legal, accounting and printing expenses and filing fees. Operating expenses are an estimate of expenditures we anticipate in operating our business, based on the level of funds realized from the line of credit.

We intend to pursue our research and product development activities, concentrating the major portion of our available resources on the shielding and filtering technologies for achieving MRI safe solutions. We have identified a core group of potential customers/development partners for our technology and continue to meet with these companies on a regular basis. We are obligated by confidentiality and nondisclosure agreements with the companies we are speaking with concerning potential relationships. We have received several term sheets from interested biomedical device manufacturers but have not accepted any of the offers at this time. However, our negotiations with these entities and our evaluation of their proposals is continuing.

Our goal is to enter into a development arrangement with one or more of these entities whereby the entity would provide financial and research support to further the commercialization of our technologies. In addition to seeking

Page

15

development arrangements with potential partners, we will continue to expand our technology portfolio by seeking to acquire complementary technologies through licensing arrangements with other third parties. Key members of our management team have and will continue to attend and present technical papers at industry trade conferences and to leaders in the pacing and medical device arena.

We estimate that our research and development plan will require approximately \$970,000 of our funds over the next twelve months, or \$526,000 if we are subject to the 9.9% limitation, dedicated to the following activities:

	Proceeds from Spectrum	9.9% Limitation
	-----	-----
MRI Shielding for Active Medical Devices	\$ 344,000	\$ 311,000
MRI Shielding for Passive Medical Devices	238,000	215,000
Photonic Technology for Intraluminal MR Imaging	388,000	-0-
	-----	-----
	\$ 970,000	\$ 526,000
	=====	=====

The MRI Shielding project entails the development of technology that may be applied to active medical devices such as pacemakers, drug pumps and others, and to passive medical devices such as biopsy needles, guidewires and others, to allow patients to undergo MRI diagnostics. The Intraluminal project involves the use of our photonic technology to develop products that improve the image quality and reduce the scan time of MRI diagnostic procedures.

Our photonic technology uses miniature electronic components to convert both power and data signals from electricity to light, thus eliminating the need for long wires inside the body. These wires are the source of unwanted heating and electrical charges that result from the magnetic and radio frequency fields used in MRI. Replacing wires with optical fibers eliminates these problems. Microcoils are a miniature version of MRI receiver coils that, rather than being external to the body as in traditional MRI, can be incorporated into a catheter and inserted inside the opening (or lumen) inside

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

the body (thus "intraluminal microcoil"). The projects will be conducted in orderly phases, first demonstrating technical feasibility, then completing detailed product designs, verifying and validating the designs. A commercialization partner will be able to intersect at any stage of development of a project.

The related party loans include a \$350,000 line of credit agreement with Biomed Solutions, LLC, which is a shareholder of Biophan and of which Michael L. Weiner, our CEO, is a manager and part owner. Currently, \$166,050 is outstanding under this agreement. The loan bears interest at 8% per annum and is due and payable in 10 equal consecutive monthly installments commencing upon the effectiveness of this registration statement. Related party loans also include a loan of \$143,570 from H. Deworth Williams, a less than 5% stockholder. This loan also bears interest at 8% per annum and is due on December 31, 2003.

Our current strategic plan does not indicate a need for material capital expenditures in the conduct of research and development activities, nor does the plan contemplate any significant change in the number of employees. We currently employ ten full-time individuals.

New Accounting Standards

Page

16

In June 2001, the Financial Accounting Standards Board (FASB) issued Statement No. 143 "Accounting for Asset Retirement Obligations" (SFAS 143). SFAS 143 addresses financial accounting and reporting for obligations associated with the retirement of tangible long-lived assets and the associated asset retirement costs. It applies to legal obligations associated with the retirement of long-lived assets that result from the acquisition, construction, development and/or the normal operation of a long-lived asset, except for certain obligations of lessees. SFAS 143 is effective for financial statements issued for fiscal years beginning after June 15, 2002. We currently are reviewing SFAS 143 and intend to implement it, if applicable, as of March 1, 2003.

In August 2001, the FASB issued Statement No. 144 "Accounting for the Impairment or Disposal of Long-Lived Assets" (SFAS 144). SFAS 144 supersedes FASB Statement No. 121 "Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to Be Disposed Of" (SFAS 121); however it retains the fundamental provisions of that statement related to the recognition and measurement of the impairment of long-lived assets to be "held and used". In addition, SFAS 144 provides more guidance on estimating cash flows when performing a recoverability test, requires that a long-lived asset (group) to be disposed of other than by sale (e.g., abandoned) be classified as "held and used" until it is disposed of, and establishes more restrictive criteria to classify an asset (group) as "held for sale". SFAS 144 is effective for fiscal years beginning After December 15, 2001. The adoption of SFAS 144 did not have a material impact on our consolidated financial condition or results of operations.

In April 2002, the FASB issued Statement No. 145 "Rescission of FASB Statements No. 4, 44 and 62, Amendment of FASB Statement No. 13, and Technical Corrections" (SFAS 145). SFAS 145 will require gains and losses on extinguishments of debt to be classified as income or loss from continuing operations rather than as extraordinary items as previously required under Statement of Financial Accounting Standards No. 4 (SFAS 4). Extraordinary treatment will be required for certain extinguishments as provided in APB Opinion No. 30. SFAS 145 also amends Statement of Financial Accounting

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

Standards No. 13 and requires that certain modifications to capital leases be treated in the same manner as sale-leaseback transactions. SFAS 145 is effective for financial statements issued after May 15, 2002, and with respect to the impact of the reporting requirements of changes made to SFAS 4 for fiscal years beginning after May 15, 2002. The adoption of the applicable provisions of SFAS 145 did not have an effect on our financial statements.

In June 2002, the FASB issued Statement No. 146, "Accounting for Costs Associated with Exit or Disposal Activities" (SFAS 146). SFAS 146 nullifies Emerging Issues Task Force Issue No. 94-3 "Liability Recognition for Certain Employee Termination Benefits and Other Costs to Exit an Activity (including Certain Costs Incurred in Restructuring)". SFAS 146 applies to costs associated with an exit activity that does not involve an entity newly acquired in a business combination or with a disposal activity covered by SFAS 144. SFAS 146 is effective for exit or disposal activities that are initiated after December 31, 2002, with earlier application encouraged. We will implement SFAS 146 as of March 1, 2003.

BUSINESS

Company History

We incorporated in the State of Idaho on August 1, 1968 under the name Idaho Copper and Gold, Inc. On February 9, 1999 we amended our Articles of

Page

17

Incorporation to change our name from Idaho Copper and Gold, Inc. to Idaho Technical, Inc. On January 12, 2000 we formed a corporation in Nevada with the intent to move our domicile to Nevada. On January 24, 2000 we implemented the change of domicile to Nevada by filing Articles of Merger between the Idaho and Nevada Corporations. On December 1, 2000 we amended our Articles of Incorporation to change our name from Idaho Technical, Inc. to GreatBio Technologies, Inc. and on July 19, 2001 we amended our Articles of Incorporation to change our name from GreatBio Technologies, Inc. to Biophan Technologies, Inc.

On December 1, 2000, we acquired LTR Antisense Technology, Inc., a New York corporation, from Biomed Solutions, LLC (formerly Biophan, LLC), a New York limited liability company, in a share for share exchange. As a result of the exchange, LTR became a wholly owned subsidiary. The exchange was consummated pursuant to and in accordance with an Exchange Agreement, dated December 1, 2000 and amended as of June 8, 2001, by and among our company, LTR and Biomed. LTR owns several patents for proprietary HIV antisense gene therapy technology.

Just prior to the acquisition of LTR Antisense, our Board of Directors consisted of Geoff Williams (President), David A. Miller (Vice President/Secretary/Treasurer), Dale F. Miller and Ed Cowle. There were 4,047,330 shares of stock outstanding including shares owned by the following control persons. Geoff Williams owned 351,000 shares (8.7%), David A. Miller owned 90,500 shares (2.2%), Dale F. Miller owned 91,500 shares (2.2%), Ed Cowle owned 851,000 shares (21%), H. Deworth Williams owned 1,398,200 shares (34.5%) and Biomed owned 718,000 shares (17.7%). There were no other control persons prior to the acquisition. The terms of the transaction were established by arms-length negotiation between Messrs. Cowle and Miller and H. Deworth Williams on behalf of our company, and Michael Weiner on behalf of Biomed, and approved by our Board of Directors and the Board of Members of Biomed. In connection with the transaction, 250,000 shares were issued to Walter Keay, an individual who acted as a finder for us in connection with the

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

transaction.

Immediately following the acquisition, the same control persons owned collectively 97.9% of Biophan.

In connection with the exchange, we:

- * issued 10,759,101 shares of common stock to Biomed in exchange for all the issued shares of LTR and
- * issued an additional 10,759,101 shares of common stock to a group of investors, consisting of Ed Cowle, H. Deworth Williams and Geoff Williams, for cash of \$175,000 in order to provide initial working capital.

Also on December 1, 2000, we acquired intellectual property rights, including a pending patent to the MRI-compatible pacemaker technology from Biomed, for future consideration of \$500,000. The assignment was consummated pursuant to, and in accordance with, the Transfer Agreement, and the related Assignment and Security Agreement, dated December 1, 2000 and subsequently amended by and between us and Biomed. The due date of this payment has been extended to be payable in twelve equal monthly installments commencing on June 1, 2004. The obligation bears interest at 8% per annum from February 28, 2002.

The Assignment and Security Agreement (i) assigns the rights to the transferred MRI patents and subsequent improvements, and (ii) provides the

Page

18

same as collateral for the payment of the \$500,000 liability under the Transfer Agreement. Both the Exchange Agreement and the Assignment and Security Agreement contain provisions for the reversion of the technology to Biomed if

- * we become bankrupt or otherwise seek protection from creditors; or
- * in the case of the MRI-compatible technology, we fail to pay the consideration therefor when due.

During 2001, we entered into a Commercial Research and Development Agreement (CRADA) with the National Institutes of Health and the University of Rochester Cancer Center, wherein these organizations conduct research and development associated with the antisense technology. This allowed us to put our full resources into the development of the MRI safety improvements to biomedical products. In 2002, we decided to discontinue research and development of the HIV antisense technology and the CRADA was terminated. While the technology holds promise and has issued patents, we feel our most promising opportunity is in the MRI safe solutions we have developed and we intend to focus our research and development activities on that technology. We may sell the HIV antisense patents if an appropriate buyer can be identified.

Company Business

Our core business is providing technology that will enable both implantable medical devices such as pacemakers, and interventional devices such as tools used inside the body during surgery, to be used safely and effectively in conjunction with MRI diagnosis, and will enable surgical procedures to be performed under real-time MRI guidance.

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

Background Terms, Facts, and Assumptions:

- * MRI is widely considered to be the premiere non-invasive imaging method due to the following capabilities:
- * Superb soft tissue contrast
- * No ionizing (x-ray) radiation that can cause cancer.
- * No toxic contrast agents such as those used in some x-ray procedures to highlight specific tissues, that can cause allergic or other reactions.
- * Images are not obstructed by bone
- * Multi-plane images can be obtained without repositioning the patient
- * The ability to use MRI to guide surgical procedures.

Due to these advantages, we believe the use of MRI will continue to increase. As the technology continues to evolve, MRI systems using higher power levels will provide better image quality. However, these advances may create greater risks to more patients and institutions that use MRI, exposing pacemaker patients to MRI creates risks and liabilities that are likely to endure for some time. We believe that a solution that can be shown to substantially reduce these risks would be readily accepted by the market. Such a solution may provide prospective licensees with the opportunity to increase their market share by offering safer devices, as well as reduce potential liabilities. Biophan's MRI-safe technology platforms could make this possible in a way that requires no changes to existing product designs, and requires very minor modifications to existing product manufacturing processes. Due to these advantages, we believe that the technologies will be attractive to commercial partners.

FDA regulations and manufacturer labeling for pacemaker devices include strict contraindications against use in an MRI environment (See Achenbach S, et

Page

19

al Am Heart J 1997;134:467-473; ECRI, Health Devices Alert, May 27, 1988, pp.1; Sherlock FG, Reference Manual for Magnetic Resonance Safety: 2002 edition, Amirsys, Inc., Salt Lake City, 2001; Zaremba L. FDA guidance for MR system safety and patient exposures: current status and future considerations / Magnetic resonance procedures: health effects and safety. CRC Press, Boca Raton Fl, pp.183-196, 2001). Contraindication means that a particular action or procedure, in this case, use in an MRI environment, is inadvisable. This pacemaker contraindication is based on evidence that induced electrical currents in the pacemaker lead can falsely pace the heart rapidly, can damage the device itself, and can create localized heating that causes tissue damage that may degrade the effectiveness of the pacing system. Independent description of these problems can be found in the following references:

1. Experimental studies showing that pacemaker electrodes could heat up to 100 C (increase of 63.1 C) within 90 seconds of MRI scanning. S. Achenbach, et.al. "Effects of MRI on Cardiac Pacemakers and Electrodes, American Heart Journal, 1997, 134, 467-473.

2. Professional opinion that "In practice, it is not possible to design a device for use in an MR environment, incorporating long metallic parts such as guide wires, mechanical cables, or electrical leads, and be completely sure of safety." Conclusions from experimental studies showing 74 C (and higher) temperature increases in guide wires after 30 seconds of MR scanning M. Konings, et.al. MEDICA MUNDI, 45/1, March 2001, page 35

3. Experimental data indicating a maximum temperature of almost 90 C and myocardial necrosis (that) could be demonstrated in histological studies. F. Duru, et.al. Pacing in MRI environment: Clinical and technical

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

considerations on compatibility. Eur Heart J, 2001, 22: 113-124.

A conservative estimate of pacemaker population worldwide is 2.5 million (See Barbaro, V.; Bartolini, P., and Bernarducci, R. Biomedical Engineering Laboratory, Istituto Superiore di Sanita, Rome, Italy. ingbio.net.iss.it {2.5 million in 1997 and growing annually). Another reference ("Interference in Implanted Cardiac Devices, Part II" by Sergio L. Pinski and Richard G. Trohman, October 2002, PACE, Vol. 25, No. 10.) cites a Japanese survey in which 17% of Japanese pacemaker patients stated that they presented conditions for which MRI would have been recommended if the device (pacemaker) had not been present. Since the practice of medicine in Japan reflects standards of care in the US and other countries where the use of pacemakers is widespread, it is reasonable to use the 17% figure across the worldwide population of pacemaker patients (2,500,000) to reach a number of 425,000 people who have at some time in the past been denied access to MRI diagnosis as a result of their pacemaker implant. Biophan has taken a conservative approach to these numbers and estimated that at least 300,000 pacemaker patients have been denied an MRI. However, currently no pacemaker patient can safely undergo an MRI and FDA regulations and manufacturer labeling for pacemaker devices include strict contraindication against use in an MRI environment.

Our shielding technology is intended for use on the lead that connects the implanted pulse generator to the electrodes that are placed in the internal heart wall. In order to eliminate risk associated with MRI for current pacemaker patients, the existing lead would need to be removed. This removal procedure is typically not done due to associated risks to the patient. As a result of this our shielding technology is intended only for future products, not previously implanted pacemakers. 600,000 people receive a pacemaker

Page

20

implant annually, and our technology could potentially be applied to all of these devices if it were adopted by all pacemaker and lead manufacturers worldwide. See http://biomed.brown.edu/Courses/BI108/BI108_1999_Groups/Cardiapacing_Team/economics.html. In addition, the shielding technology, if successfully developed, could be used as an alternative to our photonic technology for use in temporary pacing for patients with existing implanted pacemakers who need an MRI procedure.

Given the number of pacemaker patients worldwide, approximately 2.5 million in 1997, (See Barbaro, V.; Bartolini, P., and Bernarducci, R. (Biomedical Engineering Laboratory, Istituto Superiore di Sanita, Rome, Italy. ingbio.net.iss.it). A portable unit for remote monitoring of pacemaker patients. Journal of Telemedicine & Telecare. 1997; 3(2)), and the percentage of pacemaker wearers (17%) who are denied MRI as a result of the total contraindication against MRI for pacemaker wearers, a very conservative estimate of the number of patients denied access to MRI is 300,000 (See "Interference in Implanted Cardiac Devices, Part II" by Sergio L. Pinski and Richard G. Trohman, October 2002, PACE, Vol. 25, No. 10. Specifically, the authors state "In a survey of 1,567 Japanese pacemaker patients, 17% stated that they presented conditions for which MRI would have been recommended if the device (pacemaker) had not been present." The source of this statement may be found in a study entitled, "Concerns about sources of electromagnetic interference in patients with pacemakers", authors Y. Sakakibara and T. Mitsui, Jpn Heart J 1999; 40:737-743.) Although we have not updated our data from 1997, we believe our estimates used above are accurate, but conservative, because the use of pacemakers worldwide has increased since 1997.

Other medical devices also contraindicated for use with MRI could be made safe with Biophan's technologies. (See "The Reference Manual for Magnetic

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

Resonance Safety, by Dr. Frank G. Shellock, 2002 edition, Amirsys Inc., ISBN 1-931-884-00-5.). Technologies currently under development by us for MRI safety and compatibility, provide the following advantages to devices that use them:

- * Reduction of heating to long metallic components resulting from radio frequency energy and pulsed magnetic fields used in MRI;
- * Reduction of electrical currents induced in metallic components resulting from radio frequency energy used in MRI; and
- * Reduction of MR image distortion resulting from metallic or other conductive components in or near the body area being imaged.

Pacemakers are one example of implanted devices used to control organ function. Other cardiac-related devices, such as implantable cardioverter defibrillators, are used to not only pace, but to help the heart recover from episodes of dangerously high pulse rate (cardioversion) and from random chaotic behavior (defibrillation). Other stimulation devices are used to help organize the contraction of the four heart chambers to reverse the effects of congestive heart failure (CHF). Neurostimulators are being used to stimulate brain tissue and eliminate symptoms of Parkinson's disease. Electrical stimulators are also being used for bladder dysfunction. All of these devices use electrical leads similar to those in pacemakers. These devices are subject to the same heating and electrical currents and can benefit from the technologies being developed by Biophan.

Surgical placement of leads used with pacemakers and other implantable devices, placement of catheters for short-term use, and placement of more permanent devices such as stents within the circulatory system, is done by use of guidewires. These guidewires typically use long metal wires for reasons of strength, flexibility, and reliability. The use of guidewires benefits from direct, real-time visualization. MRI is preferred in many cases due in part to the fact that x-ray imaging exposes patients and physicians to radiation, and due to the improved soft-tissue imaging available with MRI. However, guidewires and long wire components in catheters are subject to the same problems associated with pacemaker leads when used in MRI. Thus, our technologies being developed can also provide benefits to these devices.

We are presently in the process of establishing one or more partnerships to complete the development process for our technologies. These partnerships may be with one or more companies involved in the manufacture and sale of:

- * components such as pacemaker leads,
- * active devices such as pacemakers that make active use of wires to conduct data and stimulating pulses,
- * passive devices such as guidewires that only make use of the physical properties of the wire elements in them, and
- * MRI diagnostics systems.

All of these potential business relationships are being pursued with the interest of funding the remaining development work, supporting necessary clinical trials and approvals, and ultimately resulting in a license for manufactured products with royalties coming to Biophan. We have received

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

several term sheets from interested biomedical device manufacturers, but we have not accepted any of the offers at this time. However, our negotiations with these entities and our evaluation of their proposals is continuing. If we do not enter into a development or licensing arrangement with any third party then we will need to obtain additional financing to continue our development efforts. In this situation, if we are unable to obtain additional financing or sell or license our technology we would have to discontinue our development efforts which may force a dissolution of the business. We do not have plans to create separate business units to pursue these opportunities.

An MRI procedure may be crucial to diagnosing colon cancer, a brain tumor, or a host of other serious, life threatening problems. The existence of a medical device that is not MRI safe and compatible requires physicians and patients to make a very difficult decision to either forego the MRI, or risk serious injury and potential death from undergoing MRI with a pacemaker, neurostimulator, or other implantable device installed. See the following references for information relating to patient deaths:

1. FDA Medical Device Report (MDR) records of pacemaker patient deaths during or shortly after an MR exam. FDA Medical Device Records (MDRs) # 351516, 748838, 175218, and 1259381:

2. Pacemaker patient who died 15 minutes after MRI scan of the brain. "Fiber Optics "Fiber Optics May Allow Pacemaker Users To Undergo MRIs Without Health Threat." The Wall Street Journal, Feb 22, 2002. D. Pennell, M.D. Imperial College, London.

3. Pacemaker patient who suffered severe brain damage and death following an MRI exam. Loss prevention case of the month. "Not my responsibility!" Journal of the Tennessee Medical Association. 1988;81(8): 523, J. K. Avery, M.D. St. Thomas Hospital, Nashville, TN.

Technology

A brief description of the terms used to describe our technologies may be helpful and is present below.

- * The term 'MRI safe' refers to a situation in which MRI testing will cause no harm to the patient or to any implantable or interventional device within them.
- * The term 'MRI compatible' refers to a situation in which image interference is minor, and the resulting MRI image is useful in diagnosing the patient's state of health.
- * The term 'active' refers to an implantable device or surgical implement that uses optical, electrical, and/or other energy to sense or transmit information, and/or modify or treat diseased tissue. Examples include pacemakers and related devices, catheter imaging devices, and drug pumps, all of which may be affected during MRI.
- * The term 'passive' refers to an implantable device or surgical

Page

22

implement that does not transmit information but serves to move, secure or modify tissue or another device, and does so via its mechanical action or presence only.

- * Carbon Composite materials consist of ultra-fine whiskers of carbon

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

dispersed in a plastic material. The resulting material has the ability to absorb and/or reflect electromagnetic energy at frequencies that relate to the size of the whiskers. This material can be extruded and molded to make components.

- * Nanomagnetic materials consist of ultra-fine particles of magnetic material (such as iron) embedded in a ceramic material. These particles are so small that they behave differently than they would in a continuous layer or solid. The choice of magnetic and ceramic materials, particle sizes, and layer thickness permit 'tuning' the nanomagnetic layer to reflect and/or absorb specific frequencies of energy. They are also so thin that they can flex without breaking and are extremely tough.
- * Filtering technology that essentially blocks unwanted induced currents at both ends of a catheter or other device.
- * Photonic technology that uses miniature diode lasers and photocells at each end of a catheter or pacemaker lead or surgical device to transmit energy and information without any electrical conductors. Diode lasers are semiconductor devices that can be as small as the size of a grain of salt that convert an electrical pulse to light at a single frequency or color. Photocells reverse this process and can also be very small. By integrating these elements carefully at each end of an optical fiber, we can send power and information without the use of wires. This technology has been made very reliable and cost effective by development in support of the telecommunications industry.
- * A further application of photonics is in intraluminal imaging. This is an extension of MRI imaging where the MRI receiver coil that is traditionally outside the body, is reduced to a very small size (microcoil) so that it can be placed inside (intra) a body cavity or blood vessel (lumen). This can provide significant improvements in resolution. We believe the performance and safety of these microcoils can be greatly improved by using our photonic technology to replace the wires currently being used by researchers to connect them to the external MRI system.

Research and Product Development Activities

We are developing technology that will enable patients with implanted biomedical devices to safely undergo MRI. We remain committed to the development of MRI-safe solutions for pacemakers and other biomedical devices. Specifically, we have been developing an MRI safe temporary pacemaker and recently conducted animal tests demonstrating this temporary pacemaker can safely pace an animal's heart. The details of this testing are discussed below. The current design of the temporary pacemaker utilizes a photonic, or fiber-optic based catheter which could be inserted into a patient prior to an MRI procedure to ensure that if their implanted device fails or malfunctions, the temporary device will keep their heart safely paced. Based on our testing and research we believe the technical and clinical feasibility of a photonic approach has already been demonstrated.

Initially we planned to develop the photonic temporary pacemaker ourselves through clinical trials, FDA approval and into commercial use.

However, we do not intend to take the device through FDA approval on our own. Instead we are offering the temporary pacemaker, along with our other MRI safe solutions, to prospective licensees for licensing and further development. To

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

date we have received licensing interest for the pacing solution, and for utilization in developing a fiber-optic catheter for an imaging application using MRI scans, called "intraluminal imaging" however, we have not yet entered any licensing or development contracts for the technology.

Our current research efforts are focused on demonstrating the feasibility of our coating and filtering solutions that we intend to license to medical device manufacturers. Initial tests of these solutions have been promising enabling us to have preliminary discussions with several companies regarding potential development arrangements. We have entered into mutual confidentiality agreements with these prospective partners although, to date, we have not executed any final agreements. Management continues to negotiate with these companies and strives to agree to definitive terms in the near future.

The results of these tests are discussed below. Until these tests were recently completed it was not clear if these solutions could solve the MRI safety issues of pacemakers and other devices. With the initial results we have achieved, it appears that these solutions can significantly reduce the heating and other problems that have caused the MRI contraindications. Our discussions with major manufacturers of pacemakers and other devices has indicated a strong preference for coating/filtering solutions versus photonic solutions for several reasons including battery life and ease of engineering redesign. To date we have received licensing interest in our technology from pacemaker, guide wire and neurological device companies but we have not yet entered into any licenses for the technology.

Our original focus was solely on pacing technology. However, following the testing of our coating and filtering technologies and the corresponding positive feedback from medical device manufactures, both inside and outside the pacing industry, we believe our potential market has been significantly increased. This increase is a result of developing technology that could be utilized by medical devices, including guide wire and neurological devices in addition to the pacemakers. As the coating/filtering technology does not require a complete product redesign and manufacturers have indicated a preference for this technology, we believe the time to commercialize our technology has been reduced. Further, we anticipate that one or more manufacturers will partner with us in developing the technology, thereby reducing our capital requirements. If we do not enter into a development or licensing arrangement with a third party for our coating/filtering technologies then we will have to obtain additional third party financing to fund these development efforts or discontinue further development of our coating/filtering technologies.

We have completed two evaluations of the fiber-optic based temporary pacemaker. Tests conducted in an active MRI environment conducted in a 'phantom' (a plastic box with gel material that mimics the body) proved operability of the device and lack of heating. An animal study demonstrated that the device can effectively pace the heart. No clinical tests on humans have been conducted and there are currently no plans to do so unless a development partner is identified and unless they assume responsibility for conducting these tests. However, animal studies such as those conducted have a good correlation to human clinical trials, since the cardiac pacing mechanisms and their similarities across species are well understood.

We believe that the combination of these tests demonstrates that a photonic

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

related to induced electrical currents and heating of the lead/tissue interface. In the test, the photonic catheter and pacemaker provided cardiac stimulation equivalent to that of a traditional electronic pacemaker. The in vitro test demonstrated that this stimulation is safely provided in the presence of electromagnetic fields associated with MRI. Additionally, the photonic catheter was found to have handling characteristics similar to traditional catheters.

The fiber-optic lead has been tested in an MRI machine and does not heat up as do existing catheters that contain metal wires. We are exploring the use of this technology with third parties, under license, for use in deep brain stimulation applications, such as treating movement related disorders like Parkinson's disease and epilepsy. We have also received OEM licensing interest from several companies wishing to use the fiber-optic lead to power intraluminal coils. We are anticipating one or more R&D contracts to help finance the development of this product that is based upon Biophan's photonic technology platform.

We have licensed, on an exclusive basis, issued patents for shielding and electromagnetic interference (EMI) filtering technologies that include the use of carbon composite and nanomagnetic particle technologies.

We have obtained a license from Johns Hopkins University for an issued patent for an MRI-safe electrocardiogram and pacemaker lead. The license is exclusive to us for implantable devices and also covers other market segments. This technology provides a low-pass radio frequency ("RF") filter at the electrode tip in the heart that permits conduction of pacemaker signals but blocks high-frequency MRI electromagnetic signals that cause problems in implanted devices.

Two tests of our technologies were recently conducted in active MRI imaging systems at imaging centers located in Western New York. The first test, showed a reduction of thermal heating caused by an MRI machine on a metal wire similar to a pacing lead that is protected by one of our MRI technologies. The control sample heated over 22 degrees Centigrade in less than one minute. With the Biophan technology added, the heating was reduced to about 1 degree Centigrade, below the level that can cause tissue damage and well within FDA safety guidelines. The second test showed a reduction of 89% in the electrical energy induced in a metal object by the MRI radio frequency field after our MRI safety technology is added to the sample.

The two tests of Biophan's coating and filtering technology were conducted on November 11, 2003 and February 13, 2003. These tests were performed in an actual magnetic resonance imaging chamber at the University Medical Imaging Center ("UMI"), located at 4901 Lac de Ville Boulevard, Rochester, New York. Both tests were run by Biophan and UMI personnel.

We have also filed patents for reducing the energy output of an MRI machine in order to minimize the energy that causes lead heating. The combination of shielding, filtering, and MRI output reduction could possibly result in solving the MRI heating problem in both active medical devices (e.g. pacemakers, defibrillators), and passive medical devices (e.g. catheters, guide wires).

We conduct our R&D and prototype development through sub-contract arrangements with third parties. Greatbatch Enterprises Corporation, a company in Clarence, New York founded and managed by Wilson Greatbatch, has developed the fiber-optic prototype temporary pacemaker for us under contract, and has

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

assigned the related patent applications to Biophan. Any future prototype work on the photonic catheter will be conducted with FDA approved manufacturers. Biophan has entered into R&D agreements with Alfred University to develop nanomagnetic shield technology, and with the University of Buffalo for carbon composite polymers (extremely fine carbon fibers in a polymer, or plastic base material). These arrangements are discussed in more detail below.

Biophan has entered into a development agreement with the UB Business Alliance (at University of Buffalo). The objective of the first phase of this collaboration focused on developing the means to shield implanted medical devices, such as a catheter, from the harmful effects of magnetic resonance imaging. The second phase of this collaboration is focusing on improving the shielding technology developed in phase one by optimizing the formulation through the use of a magnetic additive. The technology being developed by this collaboration consists of small carbon materials manufactured in a flexible polymer support. Major activities include development of optimally performing mixtures of carbon and polymer materials, the application of these optimal formulations to medical devices, and the testing of these devices in a magnetic resonance imaging system. Under the terms of the agreement for phase one of the collaboration, we paid \$23,375 toward the total project cost of \$42,994. All aspects and obligations of phase one have been completed and satisfied. Biophan will pay \$31,922 toward the total phase two project cost of \$50,539 in four equal installments of \$7,980.50. The installments are due and payable as follows: (1) upon receipt of the invoice from the UB Business Alliance (expected within the next 30 days) (2) August 29, 2003 (3) November 28, 2003 (4) within 30 days of the receipt of the final project report. Phase two of this collaboration is expected to be completed in August of 2004.

Biophan has also entered into agreements with Alfred University. The objective of this collaboration is to develop the means to shield implanted medical devices, such as pacemaker leads, from the harmful effects of magnetic resonance imaging (MRI). The technology being developed by this collaboration consists of nano-magnetic materials and the processes used to apply these materials as uniform, thin-film coatings. Major activities include the development of optimal nano-magnetic coating formulations, delivery of three coated pacemaker leads, the delivery of three coated guidewires suitable for testing, processes for applying these formulations to medical devices, and the testing of these devices in a magnetic resonance imaging system. This collaboration also provides Biophan with access to expensive, thin-film coating equipment considered essential to the development of effective nano-magnetic MRI shielding materials. Biophan has paid Alfred University \$118,000 for these services. The research and development efforts under our agreements with Alfred University will be completed as soon as the data is compiled and a final project report issued. This is expected to occur on or before July 1, 2003. In addition, the parties are discussing entering into another research and development agreement to evaluate the feasibility of applying our technology to other product applications. However, at this time no definitive agreement has been reached on collaborating on additional research projects.

While the objectives of the two collaborations are similar (i.e. the development and evaluation of MRI shielding materials), it should be understood that each collaboration is developing a different technology. The success of these collaborations would provide Biophan with multiple solutions to the MRI safety problem. Biophan considers this to be very important, since the MRI shielding requirements differ by product type, and having multiple solutions would enable us to apply our technologies to a broader range of products. Specific product technology development activities along with timelines and estimated costs, can be found in the section

"Products and Markets" below in this document.

Patents and Intellectual Property

We have been aggressive in filing patent applications on these technologies. Due to the importance of our patent portfolio it may be helpful to provide more detail regarding the patent process:

- * Once a patent is filed, the United States Patent & Trademark Office (USPTO) examines it over a period that may range from a year to two or more. USPTO action is a challenge to the content or scope of the patent, and may require one or more iterative responses to the Examiner's questions or challenges. During this process, typically after eighteen months from filing, the USPTO will publish the application, making it available on the USPTO database so that it is publicly available. Once negotiation over the office action is complete the Patent office may allow the patent, essentially informing the inventor(s) that they may pay fees and the patent will then issue, or become a formal patent.
- * As previously discussed, we have exclusive licenses, in medical device applications, to three issued patents; one each in the areas of carbon composite shielding, nanomagnetic shielding, and RF (radio frequency) filtering. RF filters are commonly used in communications equipment to block unwanted signals.
- * We have filed (42) US patent applications covering various aspects of photonic and other technologies providing improvements in MRI safety and compatibility, as well as other aspects of implantable device performance. None of these applications have yet been allowed, approximately 60% of these have been published by the USPTO, and we anticipate initial Office Actions in the near future.
- * The inventor of the nanomagnetic shield technology, Dr. Xingwu Wang, at Alfred University, New York, has applied for an additional (9) US patent applications covering further improvements extensions to that technology; these will also be licensed exclusively to Biophan for medical markets.
- * Additional patent filings in nanomagnetic materials, and in MRI microcoil designs, are in process or contemplated.

The issued patents have remaining lifetimes, as follows:

- * U.S. 6,506,972; Magnetically Shielded Conductor; 19 years
- * U.S. 5,827,997; Metal Filaments for Electromagnetic Interference Shielding; 12 years
- * U.S. 5,217,010; ECG Amplifier and Cardiac Pacemaker for Use During Magnetic Resonance Imaging; 7 years

Lifetimes for any additional patent applications that are granted as patents by the USPTO will be the greater of:

- * 17 years from the date of issue, or
- * 20 years from the date of filing
- * The patent strategy being pursued by us is based on both broad coverage at the system level and focused coverage at the component level.

- * This strategy is being applied to active medical devices such as cardiac assist devices (pacemakers and defibrillators), intraluminal imaging coils, patient monitoring instrumentation, neurostimulators, drug pumps, endoscopes; and to passive medical devices such as biopsy needles, guidewires, and to other medical devices that need to be made safe and effective in an MRI environment.

Michael L. Weiner, our President and CEO, has participated as inventor or co-inventor in a number of the patent applications currently being pursued by Biophan, each of which has been assigned to us. Throughout his employment, Mr. Weiner has, and will continue to, assign to us rights to patents that deal with MRI safety, image compatibility and HIV antisense. Biophan does not have proprietary rights in six unrelated patents in areas of technology outside of Biophan's business interests, of which Mr. Weiner is the inventor or co-inventor. One of the six patents is currently the basis for an infringement suit against LeapFrog Enterprises. This infringement suit is unrelated to the business of Biophan as is the patent upon which it is based. Of the patents assigned to entities other than Biophan for which Mr. Weiner is an inventor or co-inventor, none will be directly or indirectly competitive with Biophan. All material assignment of patent applications from Mr. Weiner to Biophan have been filed as exhibits to the registration statement, of which this prospectus is a part.

Products and Markets

We are addressing three basic areas of technology and product development that apply across several market segments:

- * MRI shielding for active medical devices.
- * MRI shielding for passive medical devices, such as guidewires and biopsy needles, enabling surgery be done under MRI guidance.
- * Photonic and shielding solutions for MRI imaging

We do not intend to produce by ourselves a product for sale, but rather to make our technologies available to other companies or partners that would like to include in their own product portfolio a new product(s) containing a our technology. We anticipate that any such product would be developed through collaboration with external companies or partners. Most likely, we would enter into licensing and R&D agreements with these partners, which ultimately could be potential sources of funding. Although we would consider lump-sum license payments, if offered, we anticipate licensing income in advance of product sales to tie up rights for each market segment, and then ongoing royalties once these products are in the market. Potential revenue streams above any negotiated minimum license payments would likely commence six to nine months following approval by the FDA for product shipments.

Following are brief descriptions of the planned development activities, each with a set of milestones with timeline and estimated Biophan cost net of any revenues. In each case, we are assuming that a commercialization partner will be identified and provide revenues, in the form of development payments, to assist us in the further development of the particular technology. The milestone projections comprehend receiving such development revenues, in each case, at the milestone/activity stage denoted as "3. Complete a Detailed Product Design", generally, during the fourth calendar quarter of 2003.

MRI shielding for active medical devices

We have licensed, developed, and patented technology in both carbon composite shielding and nanomagnetic shielding. For certain devices, this approach has the potential to provide a more cost-effective path to MRI safety and compatibility than the photonic approach. Results of direct testing in an MRI device to date have been quite promising, and further work is under way to refine the designs of materials and coating methods. This MRI shielding technology may be applied to active medical devices such as pacemakers and related devices, drug pumps, and the like. We are currently having discussions, under confidentiality agreements, with manufacturers of primary device components such as pacemaker leads, as well as manufacturers of complete systems, concerning their use of this technology. On-going research, test, and evaluation activities in nanomagnetic shielding are being done internally, and in conjunction with Dr. Wang (the inventor of the technology) at Alfred University, and Dr. Chung at the University of Buffalo. The material terms of these contracts are discussed under the heading "Research and Product Development Activities."

Milestones / Activities - MRI Shielding for Active Devices:

	MILESTONE/ACTIVITY	TIME PERIOD	REQUIRED FUNDING (000s)
1.	Demonstrate Technical Feasibility	March to June 2003	\$147
a.	Demonstrate the ability to minimize or eliminate device heating and electrical problems caused by MRI		
b.	Demonstrate the ability to meet secondary product performance requirements (e.g. biocompatibility, flexibility, etc)		
c.	Demonstrate that the technology can be manufactured at acceptable costs and quality		
d.	Continue to file related patent applications		
2.	Identify a commercialization partner(s)	March to June 2003	\$ 33
3.	Complete a Detailed Product Design	July to December 2003	\$130
a.	Further optimize the technology's performance and manufacturability		
b.	Develop detailed Product Design and Manufacturing Process Specifications		

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

4.	Complete Design Verification	October 2003 to March 2004	\$170
	a.	Demonstrate that a product manufactured to the Product Design Specifications will satisfy the Product Performance Requirements	
	b.	Develop documentation required to initiate clinical testing	
5.	Complete Design Validation	April 2004 to December 2004	\$150
	a.	Demonstrate that a product manufactured to the Product Design Specifications is clinically effective and safe when used as intended	
	b.	Develop documentation required for regulatory body approval to distribute and sell the product	
		----- TOTAL	\$630 =====

Biophan intends to identify a commercialization partner(s) to help prioritize and financially support activities (3), (4), and (5).

MRI shielding for passive medical devices

The same MRI shielding technology may be applied to a wide variety of passive devices that are used in implantable medical devices and in surgery, such as biopsy needles, guidewires, endoscopes, etc. We believe that our MRI shielding will eliminate the problems of patient risks and image degradation for passive devices and surgical implements which incorporate the technology. We are currently having discussions with a variety of manufacturers of passive devices, and involving them in test procedures we are conducting. On-going research, testing, and evaluation of this technology is also being done with Dr. Wang (the inventor of the technology) at Alfred University, and Dr. Chung at the University of Buffalo.

Milestones / Activities - MRI Shielding for Passive Devices

MILESTONE/ACTIVITY	TIME PERIOD	REQUIRED FUNDING (000s)

1.	Demonstrate Technical Feasibility	March to June 2003 \$ 90
	a.	Demonstrate the ability to minimize or eliminate device heating and electrical problems caused by MRI

b. Demonstrate the ability to meet

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

	secondary product performance requirements (e.g. biocompatibility, flexibility, etc)		
c.	Demonstrate that the technology can be manufactured at acceptable costs and quality		
d.	Continue to file related patent applications		
2.	Identify a commercialization partner(s)	March to June 2003	\$ 33
3.	Complete a Detailed Product Design	July to December 2003	\$ 95
a.	Further optimize the technology's performance and manufacturability		
b.	Develop detailed Product Design and Manufacturing Process Specifications		
4.	Complete Design Verification	October 2003 to March 2004	\$170
a.	Demonstrate that a product manufactured to the Product Design Specifications will satisfy the Product Performance Requirements		
b.	Develop documentation required to initiate clinical testing		
5.	Complete Design Validation	April 2004 to December 2004	\$150
a.	Demonstrate that a product manufactured to the Product Design Specifications is clinically effective and safe when used as intended		
b.	Develop documentation required for regulatory body approval to distribute and sell the product		

		TOTAL	\$538
		=====	

Once again, Biophan intends to identify a commercialization partner(s) to help prioritize and financially support activities (3), (4), and (5).

Photonic technology applied to a temporary pacemaker

We subcontracted the development and testing of a photonic temporary pacemaker device to Greatbatch Enterprises. This phase of the development work has been completed. The photonic temporary pacemaker is intended as a

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

backup for patients who need MRI diagnosis but who already have an implanted pacemaker or implantable cardioverter defibrillator (ICD). This device consists of:

- * An external handheld controller that is MRI safe.
- * A fiber optic lead that is biocompatible and physically similar to typical electrical pacemaker leads. This lead is temporarily inserted through a puncture and run through blood vessels to the heart.
- * The photonic electrodes at the end of the lead reconvert light to electrical signals that pace the heart in the same manner as traditional pacemakers.
- * The controller is designed to be reusable, and the lead/electrode are single use. The temporary pacemaker is available if the implanted device encounters any type of malfunction during or after the MRI procedure.

As previously noted, while the technical and clinical feasibility of a photonic approach to cardiac pacing has already been demonstrated, the results of recent Biophan R&D activities in shielding and filtering technologies has enabled a change in direction of product development. A coated temporary pacing lead is anticipated to be considerably less expensive than a photonically powered temporary pacing device. Now that we have demonstrated the feasibility of shielding and filtering of metal wire leads, the photonically based temporary pacing program has been put on hold pending interest from a corporate partner. It should, however, be noted that additional attributes of photonic technology relating to information bandwidth are applicable to the emerging market of internally-placed micro-sized MRI receiver coils (intraluminal MRI microcoils). The project is described in the next section of this document.

The initial prototype of an externally powered photonic pacemaker being developed by us was recently tested in an MRI system. The test used a "phantom" or plastic and liquid model of a human torso to permit tests for displacement due to the magnetic field, and for heating due to the RF energy. The results of this test, conducted by Dr. Frank Shellock, concluded that "the lead of the Photonic Temporary Pacemaker will not present an additional hazard or risk to a patient undergoing an MRI procedure using an MR system operating with a static magnetic field of 1.5 Tesla or less (The term static magnetic field refers to a field similar to one from a permanent magnet or the Earth's natural field. A 1.5 Tesla field is approximately 30,000 times as powerful as the Earth's field.) As such the lead of the Photonic Temporary Pacemaker that underwent evaluation should be considered "MR safe" according to the specific conditions used for testing." Shellock, F. G. "Magnetic Resonance Safety Testing of a Fiber-Optic Lead Used for the Photonic Temporary Pacemaker."

Photonic technology for intraluminal MR imaging

Our patent coverage includes the use of photonics in medical devices unrelated to implants or to cardiac pacing. One example is in a relatively

Page

32

new branch of MRI referred to as intraluminal MRI. Image quality and resolution are directly related to proximity of the MRI receiver coil to tissue being diagnosed. Traditional full-body receiver coils are large enough for the patient and support device to pass through. Smaller coils placed on the patient, near the area of interest, can provide improved images. Intraluminal (within a body opening or vessel) and intraparenchymal (within

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

tissue e.g. brain) MRI microcoils provide performance advantages that include improved image quality, reduced scan time, and the ability to utilize lower strength MRI coils. However, current MRI microcoil techniques are limited by problems similar to those that exist for pacemakers. A photonic coil interface and use of optical fiber transmission eliminate these problems, provide for other optical tissue measurements, and provide the ability to handle huge amounts of data easily. One very exciting opportunity is in the area of 'vulnerable plaque'. It is believed that up to 85% of heart attacks and strokes may be caused by rapid formation of clots at places in the artery walls that are missed by other diagnostic methods. A feature article from Scientific American, May 2002; vol.286; no.5 by Peter Libby, entitled "Atherosclerosis: The New View", describes in detail the new thinking regarding the genesis of the vast majority of heart attacks and strokes. We are currently seeking a licensee interested in developing and marketing the photonic MRI and microcoil markets. The following cost projections are only to be expended in the event of a licensee willing to fund a portion of these phases and agree to take the product to market.

We are not currently conducting, directly or indirectly, any research or development of our photonic technology and have no plans to further such efforts until an agreement is reached with a development partner. The necessary future product research, testing, and evaluation of these improvements will be done as a part of a development partnership with this partner, if and when such an agreement is reached.

Milestones / Activities - Photonic Technology for Intraluminal MR Imaging

MILESTONE/ACTIVITY	TIME PERIOD	REQUIRED FUNDING (000s)
1. Demonstrate Technical Feasibility	April to June 2003	\$ 50
a. Demonstrate the ability to minimize or eliminate device heating and electrical problems caused by MRI		
b. Demonstrate the ability to meet secondary product performance requirements (e.g. biocompatibility, flexibility, etc)		
c. Demonstrate that the technology can be manufactured at acceptable costs and quality		
d. Continue to file related patent applications		
2. Identify a commercialization partner(s)	April to September 2003	\$250
Page 33		
3. Complete a Detailed Product Design	October 2003 to June 2004	\$410
a. Further optimize the technology's performance and manufacturability		

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

b.	Develop detailed Product Design and Manufacturing Process Specifications		
4.	Complete Design Verification	July 2004 to September 2004	\$160
a.	Demonstrate that a product manufactured to the Product Design Specifications will satisfy the Product Performance Requirements		
b.	Develop documentation required to initiate clinical testing		
5.	Complete Design Validation	October 2004 to September 2005	\$500
a.	Demonstrate that a product manufactured to the Product Design Specifications is clinically effective and safe when used as intended		
b.	Develop documentation required for regulatory body approval to distribute and sell the product		
		----- TOTAL	\$1,370 =====

Once again, Biophan intends to identify a commercialization partner(s) to help prioritize and financially support activities (3), (4), and (5).

The research and development expenses incurred by us were \$113,144 for the fiscal year ended February 28, 2001, \$949,124 for the fiscal year ended February 28, 2002, and \$1,373,124 for the year ended February 28, 2003.

Markets

The global market for medical devices that could benefit from technology that will enable those devices to operate safely and effectively in an MRI environment was approximately \$5 billion in the year 2002 and is growing by 15% annually. (See Wedbush Morgan Securities' Equity Research Report 13 Mar. 2002 on NYSE-GB.

We anticipate that we will license our technology to one or more development partners who would be responsible to develop commercial products, obtain necessary approvals, manufacture, market and distribute the products.

Page 34

We expect our search for development partners will be global, although our current efforts are focused on the U.S. operations of certain multi-national companies. However, we can not presently identify or predict the precise target markets, distribution methods or other marketing efforts of our potential development partners.

Competition

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

There are a number of major companies engaged in the development of medical devices some of which may be investigating MRI safe options. However, to the best of our knowledge none of these companies, nor other companies that serve as their suppliers, have successfully developed technology enabling implantable medical devices to be operated in the presence of MRI equipment. We believe that in order to commercialize our technologies we will have to enter into a development or licensing agreement with one or more of the companies engaged in the development of medical devices.

Currently, the major providers of active medical devices contraindicated for MRI include the following companies:

Medtronic Incorporated is a leading manufacturer of cardiac rhythm management, cardiovascular and other medical devices. The company has a dominant position in cardiac pacemakers, is the leading manufacturer of implantable cardiac defibrillators, and is a major player in most other device markets in which it competes.

Guidant Corporation is also a leading manufacturer of cardiac rhythm management devices such as cardiac pacemakers, implantable cardiac defibrillators, interventional cardiology devices (including coronary stents), and other cardiac and vascular surgery devices and instruments.

St. Jude Medical, Inc. is a global developer, manufacturer, and distributor of medical device products for cardiac rhythm management, cardiology and vascular access. Other products include mechanical and tissue heart valves and vascular closure devices.

Boston Scientific Corporation is the world's largest medical device company dedicated to less-invasive therapies. The Company's products and technologies are designed to improve surgical procedures and improve patient response, and involve a range of interventional tools and procedures.

Johnson & Johnson is the world's largest healthcare company; in addition to OTC and home healthcare products, they provide a wide variety of pharmaceutical, diagnostic, and surgical products.

We do not consider the above companies to be direct competitors, although they may possibly be developing MRI safe solutions for their own product lines. Rather they may have interest in adopting one or more of our technologies into their products. Various first and second tier suppliers to these companies may be directly affected by either the photonic or shielding technologies we plan to commercialize, and since to the best of our knowledge none of them have satisfactory solutions to MRI issues, they are potential additional or alternative prospects for commercializing our technology.

Manufacturing and Component Strategy

We are developing technology for MRI safety which will be licensed to leading biomedical device manufacturers. We do not plan to manufacture any

Page

35

product or component on our own. We may provide critical components and coating devices sourced from third parties and resold to our customers.

Regulatory Approval

We believe that our technology will be incorporated into various medical devices by major manufacturers and that these manufacturers will be

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

responsible for obtaining FDA and other regulatory approvals required for clinical studies and marketing of their products. The time and cost of these activities can be substantial, especially for Class III implantable products, and could delay the introduction to the marketplace of products utilizing our technology.

Currently, the FDA, specifically The Center for Drug Evaluation and Research (CDER), is responsible for the approval to market products resulting from the technology currently being developed by Biophan. Approval to market may take the form of a New Drug Application (NDA). An NDA is sought by a company prior to the commencement of clinical testing in humans. Before approving an NDA, the FDA will seek substantial documentation demonstrating that the product candidate technology is safe and effective. Once the NDA has been approved, clinical trials are conducted in three sequential phases which may overlap. Phase I clinical trials are performed in healthy human subjects to establish initial data about the safety and efficacy of the product. In Phase II clinical trials, in addition to accumulating safety and efficacy data, the product is evaluated in a limited number of patients with the targeted disease condition. Phase III clinical trials typically involve continued testing for safety and efficacy, as well as other criteria, in expanded, large-scale, multi-center studies of patients with the targeted disease condition.

We do not intend to produce by ourself a product for sale, rather we intend to make our technologies available to other companies or partners that would like to include the technology in their own product. We believe that these companies will be willing to share a portion of the costs required to obtain FDA approval. In certain instances, the FDA may require a partner's participation if approval is being sought for modification of a partner's existing product to include our technology, a product that uses the partner's existing manufacturing processes, or a situation where a partner requires that Biophan use the partner's quality system.

We believe that the time-frame for FDA approval of our photonic technology for intra-luminal MR imaging, enabling us to make, use, and sell the product, will depend upon the following factors:

- * the FDA's classification of the photonic intra-luminal MR imaging catheter;
- * the specific ways in which a partner plans to use the product, such as the specific parts of the body they would like to image with the product (e.g. cardiovascular system, brain, etc.); and
- * the level of urgency placed on the activities required to obtain product regulatory approval

The FDA has already approved for sale intra-luminal imaging catheters that utilize electrical leads to provide power to the microcoil and to carry received signals back to the MRI system. Biophan is in discussions with one company that has such a product, and we believe that our photonic technology will permit improvements in performance due to its inherent immunity to

Page

36

electromagnetic noise created by the MRI environment. <We are under a non-disclosure agreement with this other company and it is our expectation that if we move forward to develop a photonic intraluminal imaging catheter, they will be responsible for regulatory approval and for marketing and sale of the product. There will be no competition between Biophan and any other company based on an intraluminal imaging catheter. We plan to provide technology that improves the market position of another company already in the marketplace and

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

not to develop a Biophan stand-alone product. In the event that this program moves forward, our plans provide for a contribution of \$500,000 toward regulatory approval efforts costing approximately \$1,500,000. However, the partner company will be responsible for oversight and conduct of clinical trials, and for applying to the FDA for approval.

Because sufficient information exists from already-approved products to assure the safety and efficacy of these devices in the applications we envision, we anticipate, but cannot guarantee, that the FDA will require a Pre-Market Notification, or 510(k) approval. This would be in place of a Pre-Market Approval, a more involved process usually reserved for devices that sustain human life and for which there is insufficient information to assure patient safety. A 510(k) approval will require that we demonstrate to the FDA data that the product design and intended uses of the product are substantially equivalent to a product(s) already approved by the FDA for commercial distribution in the U.S.

In the event the FDA considers the Biophan product to be a Class II Medical Device subject to 510(k) approval, we would work with a partner to collect or develop the product performance data the FDA requires to prove that the our product is substantially equivalent to intra-luminal catheters already on the market. We anticipate that collecting or developing this data would be at least a moderately high priority by a partner, and would take approximately 3-6 months to complete. Biophan and its partner would include this data in an application to the FDA for 510(k) approval, 90 days before selling the device. The FDA can refuse to allow this approval to be granted by responding with questions during the 90 day review period. Based upon this possibility, we estimate that the approval process will require a total of 180 days. Accordingly, the total time for product regulatory approval would be approximately 12 months.

The FDA has also previously approved for sale the types of active devices (pacemaker leads) and passive devices (guide wires and catheters) that we would like to improve by the addition of our magnetic resonance imaging (MRI) shielding technologies. We believe that the technology would improve the performance of these existing products during MRI examinations. The FDA considers these devices to be Class II Medical Devices, and historically they have been subject to Pre-Market Notification or 510(k) approval requirements.

We anticipate working with a partner to collect or develop the product performance data required for FDA approval of our shielding technologies. This data will include proof of the following:

- * that the product modified to include Biophan's shielding technology is still substantially equivalent to products already approved for sale by the FDA; and
- * that the addition of Biophan's shielding technology actually does improve the performance of the existing product during MRI examinations.

The addition of Biophan's shielding technology to an existing product requires that we apply a proprietary coating to the product. Because the

Page

37

coating process does not require any significant changes to the product design or to its manufacturing process and therefore little risk to the safety of its operation, we anticipate that a minimal amount of data will be required. We feel that it is reasonable to expect that the FDA will consider the 510(k) approval process they required to approve the original device, as sufficient to approve the minor modifications to a partner's device required to integrate Biophan's technology. We anticipate that collecting or

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

developing this data would be at least a moderately high priority by a partner, and would take approximately 3-6 months to complete. Biophan and its partner would include this data in an application to the FDA for 510(k) approval, 90 days before selling the device, as is required by the 510(k) approval process. The FDA can refuse to grant 510(k) approval by responding with questions during the stipulated 90 day review period. Based upon this possibility, we conservatively estimate that the approval process will require a total of 180 days. Accordingly, the total time for product regulatory approval for planning purposes is 12 months for both active and passive devices.

During the 510(k) approval process it will be necessary to collect biocompatibility and toxicity data, to establish that the modified product is safe. The FDA provides specific guidelines for evaluating the biocompatibility and toxicity risk associated with medical devices in their document entitled "Guidance for the Submission of Research and Marketing Applications for Permanent Pacemaker Leads and for Pacemaker Lead Adapter 510(k) Submissions," issued on 1 November 2000. This guidance document clearly states (Attachment C - Biocompatibility Flow Chart for the Selection of Toxicity Tests for 510(k)s") that device materials that do not contain toxic substances (as is the case with Biophan's shielding material) satisfy biocompatibility requirements. Biophan can collect this toxicity data from available toxicology literature without the need for human studies. We believe that the FDA will support this procedure and not require human studies to demonstrate biocompatibility and the absence of any toxicity risk. However if this proves not to be the case, then we expect the FDA would follow the guidelines it recommends for determining the biocompatibility and toxicity of unknown substances. These are also outlined in their guidance document entitled "Guidance for the Submission of Research and Marketing Applications for Permanent Pacemaker Leads and for Pacemaker Lead Adapter 510(k) Submissions," issued on 1 November 2000. These guidelines stipulate the use of in-vitro (out of the body) extraction methods. This testing is relatively minor in nature, and has already been included in the proposed regulatory approval timeline and budget requirements.

Demonstrating that Biophan's shielding technologies improve the products performance during MRI examinations will require evaluating the performance of the product in an MRI coil. Given the perceived low level of patient risk associated with our shielding technologies, we anticipate that these data can be obtained through testing that also does not involve human subjects and only a limited number of animals.

We anticipate that the collection and development of these data will require \$450,000 for each of the limited number of active device applications and passive device applications initially envisioned, and \$1,500,000 for the intra-luminal imaging catheter. We also anticipate that a partner or licensee would fund at least 67% of these expenses. We anticipate our contribution to come from the Spectrum equity line of credit and, if necessary, other equity investors. If we are unable to establish the partnerships or licenses that would provide a portion of the funds necessary to pursue regulatory approval then our submission of applications for regulatory approval to the FDA would be delayed, in whole or part, and our development efforts may also have to be

Page

38

delayed, in whole or part, until alternative funding was obtained.

Licenses

We have entered into licenses for issued, allowed and pending patents. These licenses require annual minimum royalties up to \$10,000 each, some of which escalate in future years, and provide for ongoing royalties of 4-5% of

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

product sales. Each license is for the life of the patent(s) and each is exclusive for the medical market or segments thereof, and permit sub-licensing:

- * a license from Johns Hopkins University for an issued patent for an MRI safe electrocardiogram and pacemaker lead. This agreement provides for an initial licensing fee of \$10,000 and a running royalty of 4% on product sales. This agreement remains in effect for the life of the patents underlying the license. The license may be terminated earlier, at Biophan's election, upon 60 days written notice to Johns Hopkins. Johns Hopkins may only terminate the agreement early if there is a breach by Biophan which is not cured within 30 days following written notice of such breach or default.
- * a license agreement for additional shielding technologies from Nanoset, LLC. This license agreement provides for a one time licensing fee of \$10,000, which is nonrefundable, and an additional payment of \$5,000 upon the issuance of the patent application(s). The seven patent applications covered by this license agreement have been assigned the following numbers by the U.S. Patent and Trademark Office:
 - 10/090,553 Magnetically Shielded Conductor
 - 10/229,183 Magnetically Shielded Conductor
 - 10/242,969 Magnetically Shielded Conductor
 - 10/260,247 Magnetically Shielded Assembly
 - 10/303,264 Magnetically Shielded Assembly
 - 10/313,738 Magnetically Shielded Assembly
 - 10/273,847 Magnetically Shielded Medical Device

The term of the license for each of the seven covered patent applications is for the life of the applicable patent. There are no termination provisions contained in the license. However, the prevailing legal case law supports the following conclusions (i) Nanoset could not terminate the license unless Biophan failed to pay the required consideration; and (ii) Biophan could not terminate the license unless it provided reasonable prior notice to Nanoset. Biophan and Nanoset are discussing granting additional technology rights to Biophan under an expanded agreement, but to date no definitive agreement has been reached.

- * a license agreement for additional shielding technologies from Nanoset, LLC. This license agreement provides for a one time licensing fee of \$10,000 and an additional payment of \$5,000 upon the issuance of the patent application(s). Additional technology rights are being explored under an expanded licensing arrangement. There are no termination provisions contained in this license.
- * a license from Deborah D. L. Chung for an issued patent entitled Metal Filament for Electromagnetic Shielding. This agreement provides for an initial licensing fee of \$10,000 and a running royalty of 5% on product sales. This agreement remains in effect for the life of the patents underlying the license. The license may be terminated earlier, at Biophan's election, upon 60 days written notice to Chung. Chung may only terminate the agreement early if there is a breach by Biophan which is not cured within 60 days following notice of such breach or default.

Employees

Page

39

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

As of February 28, 2003, we had ten full-time employees.

Description of Property

Our headquarters are located at 150 Lucius Gordon Drive, Suite 215, West Henrietta, NY 14586, in 4,000 square feet of office space leased from an unrelated party. Current rentals are \$4,475 per month and the lease expires in September 2004. The coordination of our research and development projects and the administration of our two wholly owned subsidiary companies, currently inactive, are directed from this location.

LEGAL PROCEEDINGS

We are not a party to any material legal proceedings and there are no material legal proceedings pending with respect to our property. We are not aware of any legal proceedings contemplated by any governmental authorities involving either us or our property. None of our directors, officers or affiliates is an adverse party in any legal proceedings involving us or our subsidiaries, or has an interest in any proceeding which is adverse to us or our subsidiaries.

MANAGEMENT

The officers and directors of Biophan are as follows:

Name	Age	Title
Guenter H. Jaensch	64	Chairman of the Board
Michael L. Weiner	55	Director, Chief Executive Officer, President
Robert J. Wood	64	Vice-President, Treasurer, Chief Financial Officer
David A. Miller	48	Secretary
Stuart G. MacDonald	54	Vice-President-Research and Development
Jeffrey L. Helfer	50	Vice-President-Engineering
Robert S. Bramson	64	Director
Steven Katz	55	Director
Ross B. Kenzie	71	Director

The above listed officers and directors will serve until the next annual meeting of the shareholders or until their death, resignation, retirement, removal, or disqualification, or until their successors have been duly elected and qualified. Vacancies in the existing Board of Directors may be filled by majority vote of the remaining Directors. Officers serve at the will of the Board of Directors.

Guenter H. Jaensch, PhD is the former Chairman and CEO of Siemens Pacesetter, Inc., a manufacturer of pacemakers. During his more than twenty-five years at Siemens, Dr. Jaensch held various senior executive positions prior to running Siemens Pacesetter, including President of Siemens Communications Systems, Inc. from August 1983 to March 1985, Chairman and President of Siemens Corporate Research and Support, Inc., from April 1982 to September 1991 and Chairman and CEO of Siemens Pacesetter, Inc. and Head of the Cardiac Systems Division of Siemens AG Medical Engineering Group from October 1991 to September 1994. Dr. Jaensch holds a Masters Degree in Business Administration and a Ph.D. in Business and Finance from the University of Frankfurt and taught business and statistics at the University prior to

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

joining Siemens in 1969. In 1994, he joined St. Jude Medical as Chairman and CEO of Pacesetter, Inc., a St. Jude Medical Company, and retired in 1995 to manage his personal investments. Since December 1997 he has been a director of MRV Communications, a publicly traded company which is a leading company in the fiber optic technology business. Dr. Jaensch has been a director of Biophan since March 2002.

Michael L. Weiner began his career at Xerox Corporation in 1975, where he served in a variety of capacities in sales and marketing, including manager of software market expansion and manager of sales compensation planning. In 1985, after a ten year career at Xerox, Mr. Weiner founded Microlytics, a Xerox spin-off company which developed technology from the Xerox Palo Alto Research Center into a suite of products with licenses to many companies. In January 1995, Weiner co-founded and became CEO of Manning & Napier Information Services, a Rochester-based company providing patent analytics, prior art searches, and other services. He held this position until January of 1999. In February 1999 he formed Technology Innovations, LLC, to develop and expand certain intellectual property assets. In August, 2000, Technology Innovations, LLC created a subsidiary, Biomed Solutions, LLC, to pursue certain biomedical and nanotechnology opportunities. Mr. Weiner serves on the Boards of Biomed Solutions, LLC, Technology Innovations, LLC, Speech Compression Technologies, LP (an R&D partnership commenced in 1989 to pursue compression technologies), Nanoset, LLC, and Nanocomp, LLC. Mr. Weiner holds six issued patents invented prior to the formation of Biophan which are owned by other companies that employed Mr. Weiner prior to the formation of Biophan. These patents do not involve technology that is competing or will compete with Biophan. Mr. Weiner has been CEO and a director of Biophan since December 2000.

Robert J. Wood is a Certified Public Accountant with extensive experience in public accounting and business consulting. He began his career at Price Waterhouse & Co. in 1962 after graduating from St. John Fisher College with a B.B.A. in Accounting. From 1973 to 2000, he was consecutively owner/partner of Metzger, Wood & Sokolski, CPAs (through December 1985), Mengel, Metzger, Barr & Co., LLP (through December 1990), and Wood & Company, CPAs, P.C. (through November 2000), all in Rochester, New York. In December 2000, his practice was acquired by a regional CPA firm, Eldredge, Fox and Porretti, LLP and he was engaged in business consulting until joining Biophan as full-time Chief Financial Officer in August 2001. He is a member of the New York State Society of Certified Public Accountants. A portion of Mr. Wood's time is spent assisting with the fiscal management of Biomed Solutions, LLC, a related company, for which Biophan is reimbursed.

David A. Miller was self employed from January 1998 until June 2001. Since June 2001 he has been employed by Biophan. From January 1998 through June 2000 Mr. Miller managed a retail outlet for his family's antique, gold and jewelry business. Additionally, from January 1998 until June 2001 he operated a business providing office support services. Mr. Miller has been an SEC Edgar system filing agent since November 1999. Mr. Miller has been associated with us since 1996. He has held the office of Corporate Secretary since January 30, 1999. During the period from April 22, 1998 until December 1, 2000 we were inactive. Mr. Miller provided office space for us and performed duties associated with maintaining our corporate existence. His duties included preparing and filing documents with applicable governmental agencies, maintaining stock records, stockholder relations, keeping minutes of Board of Directors and stockholder meetings and electronically filing periodic and special reports with the SEC. Since December 1, 2000 Mr. Miller has served in a similar manner consistent with the requirements of the office of Corporate Secretary. He served on the Board of Directors from April 22, 1998

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

from April 22, 1998 until December 1, 2000.

Stuart G. MacDonald is experienced in research and development with a broad engineering and science background, emphasizing a systems approach to developing complex technology. From January 1995 through December 2000, Mr. MacDonald was employed at Ortho-Clinical Diagnostics, a Johnson & Johnson company, in Rochester, New York, holding the position of Director-Engineering from 1996 to mid-1997 and Vice-president, Clinical Lab Instrumentation R & D from mid-1997 through December 2000. He was responsible for overall management of the R&D group, including personnel, administration and financial performance. He worked at Eastman Kodak Company from 1971 to 1994, rising to the position of Assistant Director, Clinical Diagnostic Research Labs. Mr. MacDonald has a B.S. in Mechanical Engineering and Masters of Engineering degree from Cornell University. He is also licensed as a professional engineer by the State of New York. Mr. MacDonald was employed by Biophan as Vice-President-Research and Development in January 2001. A portion of Mr. McDonald's time is spent assisting with the research program of Biomed Solutions, LLC, a related company, for which Biophan is reimbursed.

Jeffrey L. Helfer's background includes 28 years in new product and technology development, systems management, new business development, and regulatory affairs, having served in a number of positions at Eastman Kodak Company for 19 years until November 1994 and from December 1994 to September 2001 at Ortho-Clinical Diagnostics (OCD) in Rochester, New York, a Johnson & Johnson company. Most recently, he was program director within OCD's Product Development and Program Management Center of Excellence, where he was responsible for systems management of OCD's next-generation clinical chemistry platform. He also held positions as Program Director and Director of Regulatory Affairs from April 2000 to September 2001, Director of Engineering from January 1997 to March 2000, Director of New Business Development from February 1995 to December 1996, and headed up multiple international and corporate initiatives to improve product performance and business processes. He holds a B.S. from Rochester Institute of Technology and an M.S. from the University of Rochester, both in Mechanical Engineering. Mr. Helfer is a Johnson & Johnson certified Design for Six Sigma Black Belt and a New York State Professional Engineer. Mr. Helfer was employed by Biophan as Vice-President-Engineering in October 2001. A portion of Mr. Helfer's time is spent assisting with the research program of Biomed Solutions, LLC, a related company, for which Biophan is reimbursed.

Robert S. Bramson is an engineer and patent attorney and since 1996 has been a partner in Bramson & Pressman, a law firm that focuses on patent and technology licensing matters. Since 1996 he has also been President of VAI Management Corp., a consulting firm that specializes in patent and technology licensing. He is former head of the Computer and Technology law group of Schnader, Harrison, Segal & Lewis (where he worked from 1968 to 1989); former Vice President and General Patent and Technology Counsel for Unisys (from 1989 to 1990); founder and former CEO of InterDigital Patents Corporation, a patent licensing company (from 1992 to 1995); former Licensing Counsel for Abbott Laboratories (from 1963 to 1966); and has been Adjunct Professor of Patent Law, Computer Law and (presently) Licensing Law at Temple Law School, Rutgers Law School and Villanova Law School at different times (from 1980 to date). Mr. Bramson has been a director of Biophan since July 2001.

Steven Katz is President of Steven Katz & Associates, Inc., a technology-based management consulting firm specializing in strategic planning, corporate development, new product planning, technology licensing, and structuring and securing various forms of financing since 1982. From January 2000 until

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

Technologies, Inc., a public company engaged in the development of proprietary genes with application to agro-biotechnology. From 1983 to 1984 he was the co-founder and Executive Vice President of S.K.Y. Polymers, Inc., a biomaterials company. Prior to S.K.Y. Polymers, Inc., Mr. Katz was Vice President and General Manager of a non-banking division of Citicorp. From 1976 to 1980 he held various senior management positions at National Patent Development Corporation, including President of three subsidiaries. Prior positions were with Revlon, Inc. (1975) and Price Waterhouse & Co. (1969 to 1974). Mr. Katz received a Bachelor of Business Administration degree in Accounting from the City College of New York in 1969. He is presently a member of the Board of Directors of USA Technologies, Inc., a publicly held corporation, and several other private companies. Mr. Katz has been a director of Biophan since July 2001.

Ross B. Kenzie is a former Chairman and Chief Executive Officer of Goldome Bank, from which he retired in June 1989. He was previously Executive Vice President of Merrill Lynch & Co., in the New York worldwide headquarters, and is a former member of the Merrill Lynch & Co. Board of Directors. He is a former Director of the Federal Home Loan Bank of New York (from 1984 to 1988) and served on the boards of the National Council of Savings Institutions (from 1982 to 1986), the Federal Reserve Bank of New York, Buffalo Branch (from 1985 to 1987), and the Savings Banks Association of New York State (from 1984 to 1987). Mr. Kenzie was a Director of Millard Fillmore Hospitals (from 1982 to 1995) and is currently Past Chairman Emeritus. He served on the Board of the Kaleida Health, Education and Research Foundation (from 1998 to 2000) and is currently on its Investment Committee. He was a Director of the Health Systems Agency of Western New York (from 1988 to 1991), and was a member of the Western New York Commission on Health Care Reform (from 1987 to 1990). Mr. Kenzie was a member of the College Council of the State University College at Buffalo (from 1981 to 1998) and served as Chairman. He was a Director of the College's Foundation and a member of its Finance Committee (from 1984 to 1998) and is currently on its Investment Committee. He served on the Council of the Burchfield-Penney Art Center (from 1990 to 2001) and the Albright Knox Art Gallery (from 1983 to 1985). He is also a member of the Board, and the Chairman of the Investment Committee of the State University at Buffalo Foundation. Mr. Kenzie currently serves on the boards of several companies including the publicly held Rand Capital Corporation and many entrepreneurial ventures that are privately held, including the Boards of Members of Biomed Solutions LLC and Technology Innovations, LLC. Mr. Kenzie has been a director of Biophan since December 2000.

Committees

The Board of Directors has an Audit Committee consisting of Messrs. Bramson, Katz and Kenzie and a Compensation Committee consisting of Messrs. Bramson, Katz and Kenzie. The Audit Committee makes recommendations concerning the engagement of independent public accountants, reviews with the independent accountants the results of the audit engagement, approves professional services provided by the accountants including the scope of non-audit services, if any, and reviews the adequacy of our internal accounting controls. The Compensation Committee makes recommendations to the Board regarding executive and employee compensation and benefits.

Compensation of the Board of Directors

Non-management directors are paid an annual cash fee of \$3,500 and a per-meeting fee of \$1,000. In addition, non-management directors receive options under our Stock Option Plan described below. All directors are reimbursed reasonable expenses incurred in attending Board meetings. We maintain directors and officers liability insurance.

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

Conflicts of Interest:

Messrs. MacDonald, Helfer and Wood each spends a portion of his time on the business affairs of Biomed for which Biomed reimburses Biophan a

Page

43

percentage of their salary and benefits. Our Board of Directors periodically reviews this arrangement on a regular basis. Currently, Biomed reimburses Biophan for approximately 20% of the time of MacDonald, Helfer and Wood. The Board of Directors does not believe that any conflicts of interest arise as a result of this policy, but it monitors the relationship on an ongoing basis.

Michael Weiner devotes essentially his full business time to our company. His employment agreement with Biophan requires a majority of his time, allowing him to attend to certain administrative duties of Technology Innovations, its subsidiary, Biomed Solutions, and Speech Compression Technologies, LP, an R&D partnership holding certain assets. Mr. Weiner is a member and the manager of Biomed and of Technology Innovations. Ross Kenzie, one of the Biophan directors, is on the Board of Members of Technology Innovations and Biomed. Biomed is in the business of identifying and acquiring technologies in the biomedical field for exploitation; it is a creditor of our company pursuant to the Line of Credit Note; and it has the right to reacquire the MRI-compatible technology which it sold to us if payments are not made when due. Due to these opposing roles, conflicts of interest could arise as to the enforcement of Biomed's rights under the Line of Credit Note, the determination of which entity will acquire a particular technology and the enforcement of its rights to the MRI-compatible technology under the Transfer Agreement.

Biomed is an investor in Nanoset, and Mr. Weiner serves on the board of Nanoset. Subsequent to the formation of Nanoset and Mr. Weiner's joining their board, Mr. Weiner learned that the nanomagnetic particle technology held by Nanoset might be applicable to the MRI safety goals of Biophan. Mr. Weiner brought this technology to the attention of Biophan which eventually licensed the technology from Nanoset. Biomed holds a 33% interest in Nanoset. Biophan's license agreement with Nanoset was negotiated based on arms-length negotiations. Mr. Weiner and Mr. Kenzie each abstained from voting on whether to approve the license agreement.

Biomed has agreed that all intellectual property developed by the employees of Biomed that is in the area of MRI Safe and/or Image Compatible Technology (the "MRI Technology") and HIV Antisense shall be assigned to Biophan. Per this agreement, MRI Technology means the technology necessary to enable medical devices resistant to radio frequency and static and gradient electromagnetic fields produced by magnetic resonance imaging machines. HIV Antisense is a method of treating HIV.

Our independent directors will make all determinations and decisions relating to the issue involving Biomed described above, without the vote of either Mr. Weiner or Mr. Kenzie. In addition, the Board will act to ensure that Mr. Weiner and Mr. Kenzie discharge their obligations to Biophan in accordance with their fiduciary duties to Biophan.

Limitation on Liability of Directors

Under Nevada Revised Statutes Section 78.138, a director or officer is generally not individually liable to the corporation or its shareholders for

Page

44

any damages as a result of any act or failure to act in his capacity as a

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

director or officer, unless it is proven that:

- * his act or failure to act constituted a breach of his fiduciary duties as a director or officer; and
- * his breach of those duties involved intentional misconduct, fraud or a knowing violation of law.

This provision is intended to afford directors protection against and to limit their potential liability for monetary damages resulting from suits alleging a breach of the duty of care by a director. As a consequence of this provision, stockholders of Biophan will be unable to recover monetary damages against directors for action taken by them that may constitute negligence or gross negligence in performance of their duties unless such conduct falls within one of the foregoing exceptions. The provision, however, does not alter the applicable standards governing a director's fiduciary duty and does not eliminate or limit the right of Biophan or any stockholder to obtain an injunction or any other type of non-monetary relief in the event of a breach of fiduciary duty.

As permitted by Nevada law, Biophan's By-Laws include a provision which provides for indemnification of a director or officer by us against expenses, judgments, fines and amounts paid in settlement of claims against the director or officer arising from the fact that he was an officer or director, provided that the director or officer acted in good faith and in a manner he or she believed to be in or not opposed to our best interests. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

Scientific Advisory Board

From time to time, we call upon the advice of members of our Scientific Advisory Board who currently serve without fixed cash compensation but are each entitled to receive 8,333 options upon completion of each year of membership. The members of our Board are:

Bradford C. Berk, M.D., Ph.D.- Since 1998, Dr. Berk has been Director, Center of Cardiovascular Research; Paul N. Yu Professor and Chief of Cardiology; Charles A. Dewey Professor and Chairman of Medicine, University of Rochester Medical Center. Dr. Berk has clinical expertise in adult cardiology and scientific expertise in cardiovascular medicine, particularly vascular biology.

Herbert A. Hauptman, Ph.D.- In 1970, Dr. Hauptman joined the crystallographic group of the Hauptman-Woodward Medical Research Institute (formerly the Medical Foundation of Buffalo) of which he became Research Director in 1972. He currently serves as President of the Hauptman-Woodward Medical Research Institute as well as Research Professor in the Department of Biophysical Sciences and Adjunct Professor in the Department of Computer Science at the University of Buffalo. He was awarded the 1985 Nobel Prize in Chemistry and elected to the National Academy of Sciences in 1988.

Kevin Parker, M.S., Ph.D.- Dean Parker is a Professor of Electrical and

Page

45

Computer Engineering, Radiology, and Bioengineering at the University of Rochester. In 1998, Dr. Parker was named Dean of the School of Engineering

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

and Applied Sciences.

Henry M. Spotnitz, M.D.- Since 1994, Dr. Spotnitz has been Vice-Chairman, Research and Information Systems Department of Surgery at Columbia Presbyterian Medical Center.

Jianhui Zhong, Ph.D.- Professor Zhong joined the University of Rochester in 1997 and is currently an Associate Professor of Radiology, Physics, and Biomedical Engineering, and Director of the MRI Research Group at the University Medical Center.

Special Consultant to the Scientific Advisory Board

Ray Kurzweil, B.S.- Founder, Chairman, and CEO of Kurzweil Technologies, Inc., a technology development company, since 1995. President Clinton awarded Mr. Kurzweil the National Medal of Technology in 1999, for his invention of the Kurzweil Reading Machine for the Blind. Mr. Kurzweil was inducted into the National Inventor's Hall of Fame in 2002, and received the Lemelson-MIT Prize in 2001. Mr. Kurzweil also developed Kurzweil Voice Recognition System, and Kurzweil Music Synthesizer.

EXECUTIVE COMPENSATION

The following table summarizes the annual compensation paid to our named Executive Officers during the three years ended February 28, 2003:

Name and principal position (a)	Year (b)	Salary (c)	Securities underlying options/SARs (g)
Michael L. Weiner, CEO	2/28/01	\$ -0-	250,000
Michael L. Weiner, CEO	2/28/02	\$150,600	-0-
Michael L. Weiner, CEO	2/28/03	\$175,000	250,000
Robert J. Wood CFO	2/28/03	\$109,461	50,000
Stuart G. MacDonald Vice-President-Research	2/28/03	\$116,057	100,000
Jeffrey L. Helfer Vice-President-Engineering	2/28/03	\$113,461	100,000

Columnar information required by Item 402(a)(2) has been omitted for categories where there has been no compensation awarded to, earned by, or paid to, the named Executive required to be reported in the table during fiscal years 2001 through 2003.

Stock Options

As of June 22, 2001, the Board of Directors adopted the Biophan Technologies, Inc. 2001 Stock Option Plan. The Option Plan provides for the grant of incentive and non-qualified stock options to selected employees, the grant of non-qualified options to selected consultants and to directors and advisory board members. The Option Plan is administered by the Compensation

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

2,500,000 shares. The Compensation Committee determines the individual employees and consultants who participate under the Plan, the terms and conditions of options, the option price, the vesting schedule of options and other terms and conditions of the options granted pursuant thereto. Non-employee directors participate pursuant to the formula set forth in the Option Plan. Each Director receives an initial grant of 30,000 options, vesting equally on the first, second and third anniversaries of grant and annual grants of 10,000 options thereafter. As of February 28, 2003, we have granted options to purchase 2,489,995 shares of Common Stock under the Option Plan. To date, no options have been exercised.

The following table summarizes information concerning stock options granted to the named Executives during the last completed fiscal year ended February 28, 2003:

Name	Percent of Total Number of Securities underlying options/SARs granted (#)	options/SARs granted to employees in fiscal year	Exercise or base price (\$/Sh)	Expiration date
(a)	(b)	(c)	(d)	(e)
Michael L. Weiner, CEO	250,000	25.25%	\$.43	7/16/12
Robert J. Wood, CFO	50,000	5.05%	\$.43	7/16/12
Stuart G. MacDonald, Vice-President-Research	100,000	10.10%	\$.43	7/16/12
Page		47		
Jeffrey L. Helfer, Vice-President-Engineering	100,000	10.10%	\$.43	7/16/12

No named Executive Officer exercised options in the fiscal year ended February 28, 2003. The following table presents the number and values of exercisable and unexercisable options as of February 28, 2003:

Name	Shares acquired on exercise (#)	Value realized (\$)	Number of securities underlying unexercised options/SARs at FY-end (#) Exercisable/Unexercisable	Value of unexercised in- the-money options/SARs at FY-end (\$) Exercisable/Unexercisable
(a)	(b)	(c)	(d)	(e)
Michael L. Weiner, CEO	None	\$-0-	266,668/233,332	\$4,167/\$8,333
Robert J. Wood	None	\$-0-	56,667/93,333	\$833 /\$1,667

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

CFO				
Stuart G. MacDonald	None	\$-0-	73,334/126,666	\$1,667/\$3,333
Vice-President-R&D				
Jeffrey L. Helfer	None	\$-0-	73,334/126,666	\$1,667/\$3,333
Vice-President-Eng.				

Employment Agreements

We have Employment Agreements with all our executive officers.

Mr. Weiner's Agreement provides, among other things, for an annual salary not less than \$175,000, a rate of pay that commenced within the fiscal year ended February 28, 2002. He may be terminated by us for cause, without cause with ninety days' written notice, upon his death or disability or upon a change in control of the Corporation. In the event of involuntary termination, disability or change in control, we will pay (i) the unpaid amount of the base salary earned through the date of termination (ii) any bonus compensation earned but not yet paid; and (iii) a severance payment equal to one (1) year of his then current salary. In addition, the Executive will be immediately vested in any options, warrants, retirement plan or agreements then in effect.

In the event of termination for cause, all unexercised warrants and options, whether or not vested, shall be canceled and he will not be eligible for severance payments.

In the event of voluntary termination, all unvested warrants and options shall be canceled and he shall have three (3) months from the date of termination to exercise his rights with respect to any unexercised but vested options. He will not be eligible for severance payments.

As used in the Employment Agreement, "change in control" means the occurrence of any one of the following events:

- (1) on the date of the merger or consolidation of Biophan with another entity where the members of the Board, immediately prior to the merger or consolidation, would not immediately after the merger or consolidation, constitute a majority of the Board of Directors of the entity issuing cash or securities in the merger or consolidation, or (2) on the date of the sale or other disposition of all or substantially all of the assets of Biophan.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The table below lists the beneficial ownership of our common stock, as of July 11, 2003, by each person known by us to be the beneficial owner of more than 5% of such securities, as well as the shares of Biophan beneficially owned by each director and officer and by all directors and officers as a group.

Title of Class: Common

Name and Address of Beneficial Owner	Shares Beneficially Owned(1) (2)	Percent of Class
-----	-----	-----
*Guenter H. Jaensch(3) 964 Allamanda Drive Delray Beach, FL 33483	733,334	1.86%

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

Page	48	
*Michael L. Weiner (4) 693 Summit Drive Webster, NY 14580	8,145,144	20.18%
Edward F. Cowle 99 Park Avenue Suite 2230 New York, NY 10016	2,898,600	7.4%
Geoffrey Williams 56 West 400 Street Suite 200 Salt Lake City, UT 84101	2,389,701	6.14%
Wilson Greatbatch (5) 5935 Davison Road Akron, NY 14001	5,856,210	14.91%
*Robert S. Bramson (6) 1100 East Hector Street Suite 410 Consohocken, PA 19428	20,000	.05%
*Ross B. Kenzie (7) Cyclorama Bldg. Suite 100 369 Franklin Street Buffalo, NY 14202	20,000	.05%
*Steven Katz (8) 20 Rebel Run Drive East Brunswick	70,000	.18%
Robert J. Wood (9) 12 Peachtree Lane Pittsford, NY 14534	146,667	.38%
Stuart G. MacDonald (10) 4663 East Lake Road Pultneyville, NY 14538	163,334	.42%
Jeffrey H. Helfer (11) 1153 Hidden Valley Trail Webster, NY 14580	203,334	.52%
David A. Miller 4004 Sunnyside Road Sandpoint, ID 83864	100,500	.26%
All Officers and Directors as a group (9 persons)	9,602,313	23.33%

* Member of the Board of Directors

(1) Except as may be set forth below, the persons named in the table have sole voting and investment power with respect to all shares shown as beneficially owned by them.

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

Page

49

- (2) Applicable percentage of ownership is based on 38,904,314 shares outstanding as of July 11, 2003, together with applicable options for such shareholder. Beneficial ownership is determined in accordance with the rules of the SEC and includes voting and investment power with respect to shares. Shares subject to options or warrants currently exercisable or exercisable within 60 days after July 11, 2003 are deemed outstanding for purposes of computing the percentage ownership of the person holding such options or warrants, but are not deemed outstanding for computing the percentage of any other shareholder.
- (3) Includes 433,334 shares issuable upon exercise of options and warrants granted to Dr. Jaensch which shares he has the right to acquire within 60 days.
- (4) Michael L. Weiner is a member and the manager of Technology Innovations, LLC, which is the majority owner of Biomed Solutions, LLC. Mr. Weiner is also the Manager of Biomed. Mr. Weiner's calculation includes 662,857 shares owned beneficially and of record by Biomed and 300,644 shares owned beneficially and of record by Technology Innovations. Includes 1,145,172 shares issuable to Biomed upon exercise of warrants issued to Biomed, 2,068,966 shares issuable to Biomed upon conversion of \$166,050 outstanding as of July 11, 2003 on the line of credit described in Note 4 under Certain Transactions, and 3,448,276 shares issuable to Biomed upon conversion of the \$500,000 transfer agreement payment, as described in Note 5 under Certain Transactions. It also includes 283,334 shares issuable upon exercise of options granted to Mr. Weiner, which shares Mr. Weiner has the right to acquire within 60 days.
- (5) Includes 5,379,550 shares owned of record and beneficially by Greatbatch Gen-Aid, Ltd., an entity owned by Wilson Greatbatch, and 109,993 shares owned by E. & W.G. Foundation, a private foundation of which Mr. Greatbatch is co-trustee. Also includes 216,667 shares issuable upon exercise of options granted to Mr. Greatbatch, which shares Mr. Greatbatch has the right to acquire within 60 days, and includes 150,000 warrants issued in connection with the Transfer Agreement with Biomed.
- (6) Includes 20,000 shares issuable upon exercise of options granted to Mr. Bramson, which shares he has the right to acquire within 60 days.
- (7) Includes 20,000 shares issuable upon exercise of options granted to Mr. Kenzie, which shares he has the right to acquire within 60 days. Does not include shares owned beneficially or of record by Biomed or by Technology Innovations. Mr. Kenzie is the Manager and an equity member of Biophan Ventures, LLC, which is the 43% equity member in Biomed; he is also the Manager of Patent Ventures LLC, which is the Class A Member of Technology Innovations. Mr. Kenzie and Mr. Weiner comprise the Board of Members of Biomed; Mr. Kenzie serves on the Board of Members of Technology Innovations.
- (8) Includes 20,000 shares issuable upon exercise of options granted to Mr. Katz, which shares he has the right to acquire within 60 days.
- (9) Includes 86,667 shares issuable upon exercise of options and warrants granted to Mr. Wood, which shares he has the right to acquire within 60 days.

- (10) Includes 103,334 shares issuable upon exercise of options and warrants granted to Mr. MacDonald, which shares he has the right to acquire within 60 days.
- (11) Includes 103,334 shares issuable upon exercise of options and warrants granted to Mr. Helfer, which shares he has the right to acquire within 60 days.

CERTAIN TRANSACTIONS

- (1) Michael L. Weiner, President and Chief Executive Officer of Biophan, is the Manager and a 42.7% equity member of Technology Innovations, LLC., a 57% equity member of Biomed Solutions, LLC (formerly Biophan, LLC). Mr. Weiner is also the Manager of Biomed. He and Ross Kenzie make up the Board of Members of Biomed. Biomed is the record owner of 662,857 shares of common stock of Biophan; Technology Innovations is the record owner of 300,644 shares of common stock of Biophan. As Manager of Technology Innovations and Biomed, Mr. Weiner has control over these entities. Mr. Weiner is also on the board of Nanoset, LLC, an entity owned in part by Biomed Solutions, and with which the we have entered into a technology license agreement.
- (2) On December 1, 2000, Biomed received 10,759,101 shares of Biophan's common stock in exchange for its shares of LTR Antisense Technology, Inc. Most of those shares have been distributed to the members of Biomed and their members.
- (3) Also on December 1, 2000, Biomed transferred its MRI-compatible pacemaker patent pending and related technology to Biophan for a future payment of \$500,000. This payment bears interest at 8% per annum from February 28, 2002, and has been extended several times, to June 1, 2004. After June 1, 2004, principal and interest are payable in 12 equal monthly installments. After November 30, 2002, this entire obligation is convertible into common shares of Biophan at a conversion price equal to the lowest of (i) the closing bid price on June 4, 2002; (ii) the closing bid price on the date of exercise; or (iii) the lowest per share purchase price paid by any third party between June 4, 2002 and the exercise date.
- (4) On June 4, 2002, we executed a line of credit agreement with Biomed providing for borrowings up to \$250,000. On August 19, 2002, the line was increased \$100,000 and the expiration date thereof for that portion of the line was set at August 19, 2003. The payment date of amounts borrowed under the original Line was extended to December 1, 2002. On November 7, 2002, the maturity date of the Line was extended until such time as the financing contemplated by the common stock purchase agreement commences; thereafter, it is payable over time as Biophan receives proceeds from the equity line.
- (5) Biomed also holds a total of 1,180,000 warrants to purchase shares of Biophan common stock. On March 1, 2001, it received options to purchase 200,000 shares at an exercise price of \$1.00, in consideration of management effort and expense incurred on behalf of Biophan. On June 4, 2002, it received 100,000 warrants at an exercise price of \$1.00 in consideration of the extension of the due date for the Transfer Agreement payment, and 75,000 warrants with an exercise price of \$1.00 for the grant of the line of credit. (Wilson

Greatbatch also received 150,000 warrants in consideration of the extension of the due date of the Transfer Agreement. On August 19, 2002, Biomed received 30,000 warrants in consideration of the increase in the line of credit commitment, and 275,000 warrants for additional extensions of the payment terms of the Transfer Agreement payment. On that date, the exercise price for all 680,000 warrants then outstanding to Biomed was set at the lowest of (i) the closing bid price on June 4, 2002; (ii) the closing bid price on the date of exercise; or (iii) the lowest per share purchase price paid by any third party between June 4, 2002 and the exercise date. On November 7, 2002, Biomed was granted warrants to purchase an additional 500,000 shares at an exercise price of \$.50 per share, in consideration of the final extension of the Transfer Agreement payment approved that day. The number of warrants will be reduced by 16,667 for each month prior to June 1, 2005 that the Transfer Agreement obligation is paid in full. Each extension of the Transfer Agreement payment enabled us to retain the MRI-compatible technology that it acquired under the Transfer Agreement. In each forgoing case, the Board of Directors determined, without the vote of Mr. Weiner and Mr. Kenzie, that the consideration received by us was fair and adequate consideration for the warrants issued.

- (6) During the years ended February 28, 2003 and 2002, Biomed and Technology Innovations paid expenses on behalf of Biophan aggregating \$128,411 and \$253,014, respectively. These advances did not bear interest and were subsequently repaid.
- (7) On January 1, 2001, Wilson Greatbatch was granted 250,000 options for his consulting services to us, and 8,333 options as former Chairman of the Scientific Advisory Board. As a consultant Mr. Greatbatch assisted Biophan in its development of its photonic pacemaker by providing design and engineering services. The board of directors determined that the value of the consulting services was fair and adequate consideration for the options issued; Biophan recorded compensation expense of \$9,200 with respect to those options. Through his ownership of Greatbatch Gen-Aid, Ltd. and his co-trusteeship of a private foundation, E.& W.G. Foundation, he is the beneficial owner of 5,489,543 common shares of Biophan. He is also entitled to receive 60% of the consideration payable to Biomed (\$500,000) for transfer of the MRI-compatible pacemaker technology to Biophan; on June 4, 2002, he received 150,000 warrants with an exercise price of \$1.00 in consideration of the extension of the payment due under the Transfer Agreement. Greatbatch Gen-Aid holds a 3.5% membership interest (11 Units) in Technology Innovations.

On February 28, 2001, we entered into a research and development agreement with Greatbatch Enterprises Corporation. Wilson Greatbatch, a beneficial owner of more than 5% of our common stock, is the CEO and majority stockholder of Greatbatch Enterprises. Under the agreement, Greatbatch Enterprises undertook certain technology development and testing, for which we paid Greatbatch Enterprises an aggregate of \$297,000. The agreement terminated in December 2002 with the completion of animal testing by Greatbatch Enterprises.

- (8) On March 1, 2002, Dr. Guenter H. Jaensch was granted options to purchase 250,000 shares and on 7/16/02 was granted an additional 100,000 options, for his consulting services to us. As a consultant,

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

Dr. Jaensch assisted us in developing our strategic plan, attended trade shows, and arranged and met with potential customers and strategic partners. The Board of Directors determined that the value of the consulting services was fair and adequate consideration for the options issued; Biophan valued the options at \$36,900 and \$592,500, respectively.

DESCRIPTION OF SECURITIES

The following summary is a description of the common stock of Biophan and Biophan's Certificate of Incorporation and Bylaws.

General

Biophan's authorized capital consists of 60,000,000 shares of common stock, par value \$.005 per share.

Common Stock

As of February 28, 2003, Biophan had outstanding 37,634,693 shares of common stock. Each share of common stock is entitled to one vote at all meetings of shareholders. Shareholders are not permitted to cumulate votes in the election of directors. All shares of common stock are equal to each other with respect to liquidation rights and dividend rights. There are no preemptive rights to purchase any additional shares of common stock. In the event of liquidation, dissolution or winding up Biophan, holders of the common stock will be entitled to receive, on a pro rata basis, all assets of Biophan remaining after satisfaction of all liabilities and preferences of outstanding preferred stock, if any. Neither the certificate of incorporation nor the by-laws of Biophan contain any provisions which limit or restrict the ability to take over our company.

Options and Warrants

We have outstanding options to purchase an aggregate of 2,489,995 shares of common stock pursuant to our 2001 Stock Option Plan, to directors, officers, key employees and consultants, of which 1,496,666 were exercisable. No options have been exercised to date. The following chart sets out the material terms of the options:

Optionholders	Number of Options Granted	Exercise Price	Expiration Dates
Non-management directors	530,000	\$.10 - \$.50	3/19/06 - 7/16/12
Employees	1,275,000	\$.43 - \$.50	1/1/11 - 7/16/12
Consultants	560,000	\$.50 - \$1.00	1/1/11 - 12/4/11
Scientific Advisory Board	124,995	\$.50	2/1/07
TOTAL	----- 2,489,995 =====		

We also have outstanding warrants to purchase an additional 4,729,706 shares of our common stock. The following chart sets out the material terms of the warrants:

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

Page

53

Warrantholders	Number of Warrants	Exercise Price	Expiration Dates
Bridge Lenders	246,627	\$1.00	6/15/04
Biomed Solutions, LLC	1,180,000	\$.145-\$.50	11/7/07
Wilson Greatbatch	150,000	\$1.00	6/4/04
CFG Capital ,LLC	121,572	\$.16-\$.41	11/11/05 - 7/30/07
Westbay Shareholders	1,385,275	\$.25	3/27/04 - 7/9/05
Westbay Shareholders	1,385,275	\$.50	3/27/04 - 7/9/05
Boylan, Brown, et al	161,290	\$.31	1/7/08
Others	99,667	\$1.00	7/30/07
TOTAL	4,729,706		

CERTAIN STATUTORY PROVISIONS OF THE NEVADA REVISED STATUTES

Sections 78.411 through 78.444 of the Nevada Revised Statutes provides, in general, that a stockholder acquiring more than 10% of the outstanding voting shares of a publicly-held Nevada corporation subject to the statutes (an "Interested Stockholder") may not engage in certain "Combinations" with the corporation for a period of three years subsequent to the date on which the stockholder became an Interested Stockholder.

Section 78.416 defines the term "Combination" to encompass a wide variety of transactions with or caused by an Interested Stockholder in which the Interested Stockholder receives or could receive a benefit on other than a pro rata basis with other stockholders, including mergers, certain asset sales, certain issuances of additional shares to the Interested Stockholder or transactions in which the Interested Stockholder receives certain other benefits.

These provisions could have the effect of delaying, deferring or preventing a change of control of our company. Our stockholders, by adopting an amendment to the Certificate of Incorporation or Bylaws of the Company, may elect not to be governed by these provisions. Neither our Certificate of Incorporation nor Bylaws currently excludes us from these restrictions.

The Nevada Revised Statutes permit a corporation to indemnify its directors and officers against expenses, judgments, fines and amounts paid in settlement in cases brought against the officer or director in his capacity as such, provided the director or officer acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation. The exceptions include a breach of the director's duty of loyalty, acts or omissions not in good faith or which involve intentional misconduct or knowing a violation of law, and improper personal benefit. The

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

Company's By-Laws contain a provision implementing this statute.

Transfer Agent

Biophan's transfer agent for the common stock is Continental Stock Transfer & Trust Company, 17 Battery Place, New York, NY 10004-1123.

SHARES ELIGIBLE FOR RESALE

Future sales of substantial amounts of common stock in the public market

Page

54

could adversely affect market prices prevailing from time to time. Under the terms of this offering, the shares of common stock offered, or the common shares underlying the warrants, may be resold without restrictions or further registration under the Securities Act of 1933, except that any shares purchased by our "affiliates," as that term is defined under the Securities Act, may generally only be sold in compliance with Rule 144 under the Act.

Certain shares of outstanding common stock were issued and sold by Biophan in private transactions in reliance upon exemptions from registration under the Act. Such shares may be sold only pursuant to an effective registration statement filed by Biophan or an applicable exemption, including the exemption contained in Rule 144 promulgated under the Act.

In general, under Rule 144 as currently in effect, a shareholder, including an affiliate of Biophan may sell shares of common stock after at least one year has elapsed since such shares were acquired from Biophan or an affiliate of Biophan. The number of shares of common stock which may be sold within any three-month period is limited to the greater of: (i) one percent of the then outstanding common stock or (ii) the average weekly trading volume in the common stock during the four calendar weeks preceding the date on which notice of such sale was filed under Rule 144. Certain other requirements of Rule 144 concerning availability of public information, manner of sale and notice of sale must also be satisfied. In addition, a shareholder who is not an affiliate of Biophan and who has not been an affiliate of Biophan for 90 days prior to the sale and who has beneficially owned shares acquired from Biophan or an affiliate of Biophan for over two years may resell the shares of common stock without compliance with the foregoing requirements under Rule 144.

RESTATED COMMON STOCK PURCHASE AGREEMENT

Effective November 22, 2002, we entered into a restated common stock purchase agreement with Spectrum Advisors, Ltd., for the future issuance and purchase of shares of our common stock. This agreement restates and supersedes the common stock purchase agreement entered into June 6, 2002 with Bonanza Capital, upon essentially the same terms and conditions. This common stock purchase agreement establishes what is sometimes termed an equity line of credit or an equity draw down facility.

After taking into account shares currently reserved for issuance under all outstanding convertible securities, we have 9,628,365 authorized common shares available for issuance. We are registering 8,960,000 of these shares for possible issuance and sale by Spectrum under the common stock purchase agreement, and an additional 448,000 common shares which will underlie warrants issuable to Carolina Financial if all 8,960,000 shares are issued under the common stock purchase agreement.

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

Draw Downs

In general, the draw down facility operates as follows. At our sole discretion and from time to time over the course of 24 months, we may make unlimited draw down requests, pursuant to which the investor, Spectrum, is obligated to purchase up to an aggregate of \$3.0 million of our common stock. Spectrum's minimum commitment for each draw request is \$37,500. The maximum amount we can actually draw for each request is limited to 30% of the volume weighted average price of our common stock multiplied by the average daily trading volume multiplied by the number of trading days in the applicable draw down period. We are under no obligation to request a draw down during

Page

55

any period or, in the absence of such a request, to issue any shares to Spectrum. If, on any day during the draw down period, the average volume weighted price of our common stock drops below the minimum threshold price of \$.18, then that day will be excluded from the relevant settlement and the aggregate amount of our draw down request will be reduced accordingly.

The draw down period will be 3 consecutive trading days. After each 3-trading-day settlement period, the final draw down amount for that settlement period is determined. We are entitled to receive funds on the 5th, 8th, 11th, 14th, 17th, 20th and 23rd trading day of each month. The final draw down amount will be reduced by 1/3rd for each trading day during the draw down period that the volume weighted average stock price falls below the threshold price. We then use the formulas in the common stock purchase agreement to determine the number of shares that we will issue to Spectrum in return for the final draw down amount. The aggregate total of all draw downs under the equity draw down facility cannot exceed \$3.0 million. However, we may, at our option, increase Spectrum's commitment up to 50% of our market capitalization at the time of exercise of the option, not to exceed \$10.0 million. Using our current market capitalization, and subject to the limits on daily draw-down amount, we could increase Spectrum's commitment to approximately \$6,000,000.

The per share price that Spectrum pays for our common stock for each draw down includes a 20% discount to the average daily market price of our common stock for each day during the draw down period, weighted by trading volume during each such trading day. The price per share that Spectrum ultimately pays is determined by dividing the final draw down amount by the number of shares that we issue to Spectrum.

Finally, the common stock purchase agreement does not permit us to draw funds

Page

55

if the issuance of shares of common stock to Spectrum pursuant to the draw down would cause Spectrum to beneficially own more than 9.9% of our issued and outstanding common stock at the time of issuance. In such cases, we will not be permitted to issue the shares otherwise issuable pursuant to the draw down and Spectrum will not be obligated to purchase those shares. Of course, any of Spectrum's resales of shares would reduce the number of shares it beneficially owns, and would enable us to issue additional shares to Spectrum subject once again to the 9.9% limitation.

The Draw Down Procedure And The Stock Purchases

We may request a draw down by faxing to Spectrum a draw down notice, stating the amount of the draw down that we wish to exercise and calculating the number of shares to be issued thereunder.

Amount Of The Draw Downs

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

No draw down can be less than \$37,500. The amount may be increased to 30% of the weighted average price of our common stock for the 3 days in the draw down period, ending on the day prior to the date of our request, multiplied by the average daily trading volume for the 3 days in the draw down period ending on the day prior to the date of our request, multiplied by the number of trading days in the draw down period. Additionally, if any of the following events occur during the draw down period, the investment amount for that draw down period will be reduced by 1/3 and the volume weighted average price of any trading day on which the event occurred will have no effect on the pricing of the shares purchased during that draw down period:

- * the volume weighted average price is less than the minimum threshold price of \$.18; or

Page

56

- * trading in our common stock is suspended for more than three hours, in the aggregate, on any trading day or if any trading day is shortened because of a public holiday.

Number Of Shares Purchased During A Draw Down

The 3 trading days immediately preceding the draw down notice are used to determine the number of shares that we will issue in return for the money provided by Spectrum, which then allows us to calculate the price per share that Spectrum will pay for our shares.

To determine the number of shares of common stock that we can issue in connection with a draw down, calculate 1/3 of the draw down amount (i.e., \$12,500). This amount will be referred to as the "per-day draw down amount." Then, for each of the 3 trading days immediately preceding the date on which we give notice of the draw down, divide the per-day draw down amount by 80% of the volume weighted average daily trading price of our common stock for that day. This 80% accounts for Spectrum's discount. The sum of these 3 daily calculations produces the number of common shares that we will issue, unless, as described above, the volume weighted average daily price for any given trading day is below the threshold amount, or trading is suspended for any given trading day, in which case that day is ignored in the calculation.

Sample Calculation Of Stock Purchases

The following is an example of the calculation of the number of shares we would issue to Spectrum in connection with a draw down based on the assumed daily prices set forth.

Day	VWAP	Minimum Commitment	Number of Shares
1	\$.445	\$12,500	28,090
2	\$.46	\$12,500	27,174
3	\$.485	\$12,500	25,773

Closing The Transaction

The delivery of the requisite number of shares and payment of the draw down will take place through our attorneys, Boylan, Brown, Code, Vigdor & Wilson, LLP, acting as escrow agent. The escrow agent pays the net proceeds to us, after subtracting its escrow fee and Carolina's placement agent fees. We would receive the amount of our draw down of \$37,500 less a 10% cash fee paid to Carolina of \$3,750 less a \$250 escrow fee, for net proceeds to us of approximately \$33,500.

We have paid \$10,000 to cover the fees and expenses of purchaser's counsel,

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

and will pay an additional \$15,000 on the first settlement date. Carolina will receive warrants to purchase 5% of the shares sold to Spectrum (up to 448,000 shares of our common stock) at a price equal to 110% of the selling price to Spectrum. Carolina is not obligated to purchase any of our shares pursuant to the common stock purchase agreement.

Indemnification Of Spectrum

Spectrum is entitled to customary indemnification from us for any losses or liabilities suffered by it based upon material misstatements or omissions from the common stock purchase agreement, registration statement and the prospectus, except as they relate to information supplied by Spectrum to us for inclusion in the registration statement and prospectus.

Page

57

SELLING STOCKHOLDERS

All of the securities being offered hereunder are being offered by the selling shareholders. These holders fall into four categories:

- * those who will obtain their shares pursuant to or in connection with the stock purchase agreement;
- * those who obtained their shares (or warrants with underlying common shares) in a private placement of securities recently conducted by the Company; and
- * Biomed Solutions, LLC, which can obtain its shares upon exercise of warrants granted in consideration of loans to, or forbearance upon amounts due from, Biophan.

The Restated Stock Purchase Agreement

The 8,960,000 common shares registered for resale by Spectrum under this prospectus would constitute 14% of our issued and outstanding common shares after such resale. We are registering the maximum number of authorized but unissued and unreserved shares that we have available at this time for sale under the stock purchase agreement. If we do not issue a draw down request, we are under no obligation to issue any shares to Spectrum under the common stock purchase agreement. Accordingly, the number of shares we are registering for issuance under the common stock purchase agreement may be higher than the number we actually issue under the common stock purchase agreement. However at our current market price, this is not enough shares to draw down the full \$3,000,000 available under the stock purchase agreement. Unless our average market price rises above \$.42, we will need to have our shareholders authorize more shares and file a new registration statement with the SEC, which will need to become effective before we can request additional draw downs under the common stock purchase agreement.

Spectrum

Spectrum is engaged in the business of investing in publicly traded equity securities for its own account. Spectrum's principal offices are located at 38 Hertford Street, London, England. We understand that Spectrum's beneficial owner is Pierce Loughran of London, England. Investment decisions for Spectrum are made by its board of directors. Spectrum does not currently own any of our securities as of the date of this prospectus. Other than Spectrum's obligation to purchase common shares under the common stock purchase agreement, it has no other commitments or arrangements to purchase or sell

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

any of our securities. There are no business relationships between Spectrum and us other than as contemplated by the common stock purchase agreement.

Carolina Financial

Carolina has acted as placement agent in connection with the common stock purchase agreement. Carolina introduced us to Spectrum and assisted us with structuring the equity line of credit with Spectrum. Carolina's duties as placement agent were undertaken on a reasonable best efforts basis only. Carolina will receive warrants for 5% of the shares purchase by Spectrum, at an exercise price of 110% of the selling price to Spectrum. It made no commitment to purchase shares from us and did not ensure us of the successful

Page

58

placement of any securities. Other than the shares underlying its warrants which are registered for resale hereunder, Carolina does not own any of our shares.

The four principals and beneficial owners of Carolina are William Prather, Robert Cascella, Michael Niederswiecki, and Michael Mascia; they have also been issued warrants to purchase a total of 121,572 warrants, consisting of 50,000 warrants at an exercise price of \$.39 per share, 17,520 shares at an exercise price of \$.41 per share, and 54,052 shares at an exercise price of \$.16 per share. These warrants were granted for their efforts as placement agent in other private placements undertaken by us and for financial advisory services, and the underlying common shares have also been registered for resale hereunder. None of these individuals held any position or office or had any other material relationship with us or any of our affiliates within the past three years. To our knowledge, after this offering, none of them will own shares of our common stock.

Spectrum and Carolina or any of their affiliates have not held any positions or offices or had material relationships with us or any of our affiliates within the past three years other than as a result of the ownership of our common stock. If, in the future, Spectrum's or Carolina's relationship with us changes, we will amend or supplement this prospectus to update this disclosure.

Westbay

Westbay Consulting, Inc., a Nevada corporation beneficially owned by Jason Cope, acted as finder and consultant to Biophan in connection with the recently-completed private placement described below. In consideration for introducing prospective investors to Biophan, we paid Westbay cash compensation of \$107,503 and, additionally, 258,006 shares of our common stock, which shares are not included for sale pursuant to this prospectus. The cash compensation was based on an amount equal to 10% of the investment proceeds we realized from the efforts and introductions of Westbay. The stock compensation was based on an amount equal to 6% of the aggregate shares purchased by investors as a result of the efforts and introductions of Westbay. The shares issued to Westbay were valued at \$.25 per share. Except in its capacity as a finder and consultant, neither Westbay or any principal of Westbay, has had any office or directorship, or any other material relationship with us during the past three years. To the best of our knowledge, following the completion of this offering, Westbay will own less than 1% of our outstanding shares.

On August 14, 2001, the SEC obtained a final judgment from the U.S. District Court for the Southern District of New York against Jason Cope and three other defendants. Mr. Cope and the other defendants were ordered to pay a total of \$19.4 million in disgorgement, interest and civil penalties. The SEC

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

originally filed a complaint on January 7, 2000 against Milan Capital Group, Inc., alleging that Milan unlawfully offered and sold IPO securities without being registered as a broker-dealer. The SEC amended its complaint on February 29, 2000 charging Mr. Cope and others with violating the antifraud provisions of the federal securities laws. On November 9, 2000, the Court granted the SEC's motion for partial summary judgment against Mr. Cope and others. On December 29, 2000, the Court entered a final judgment of Permanent Injunction against Mr. Cope and others, enjoining them from further violations of the antifraud provisions of the securities laws. Mr. Cope appealed the judgment, but the appeal was later dismissed for failure to prosecute. The final judgment entered in August 2001 called for \$9.4 million for disgorgement and prejudgment interest, and further ordered Mr. Cope and a second defendant to pay a civil penalty of \$10 million. Until after the completion of the private placement Biophan was unaware that Mr. Cope had previously been convicted of violations of the securities laws and Mr. Cope did not otherwise inform Biophan, or its legal counsel, of this past history. If Biophan had been aware of Mr. Cope's prior violations of the securities laws it would not have hired Westbay to assist it in its private placement.

The SEC has informed Biophan that in the opinion of the Division of Market Regulation, Westbay acted as an unregistered broker-dealer in connection with Biophan's private placement. The SEC further alleges that those selling shareholders that acquired Biophan shares in the private placement may have acquired their shares in violation of federal securities laws. Although Biophan believes that Westbay acted as a finder and not a broker-dealer in connection with the private placement, there can be no assurance that the SEC will not find otherwise. Biophan further believes that the private placement complied with the provisions of Regulation D and Rule 506 of the Securities Act of 1933, and was exempt from the registration provisions of the Securities Act. However, there can be no assurance that the SEC will not conclude that the private placement was defective or that the exemption from registration was not available. Without further information from the SEC, we are unable to predict the possible consequences to Biophan or the selling shareholders should an adverse finding against Westbay or Biophan be made by the SEC.

Biomed

Biomed Solutions, LLC is the New York limited liability company which transferred the MRI technology and the shares of LTR Anti-sense Technology, Inc. to us on December 1, 2000. The beneficial owners of Biomed included Michael Weiner, Ross Kenzie and 50 investors. It is a shareholder of Biophan and its Manager is Michael L. Weiner, who is the President and Chief Executive Officer and a Director of Biophan. Biomed has received warrants to purchase a total of 1,180,000 common shares, partially as consideration for making available a line of credit to us and for forbearance of payments relating to the MRI technology transfer. We are registering herewith the shares underlying those warrants, for resale by Biomed. Following this offering, Biomed will own 662,857 shares of Biophan.

The Private Placement

Page

59

From September 2002 through January 6, 2003, we raised gross proceeds of \$1,385,275 by selling 5,541,100 shares at a per share price of \$.25 to 117 investors. Those investors also received warrants to purchase an additional 2,770,550 shares, half at an exercise price of \$.25 per share and half at \$.50 per share. These shareholders, except for Westbay Consulting, Inc., were granted registration rights, and their shares (including the shares underlying the warrants) are registered for resale hereunder. The names of these selling shareholders, and the number of shares offered hereunder are set forth below.

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

None of these shareholders held an office or directorship or had any other material relationship with us during the past 3 years, except that Guenter Jaensch, Jeffrey L. Helfer, Stuart McDonald and Robert J. Wood are officers and/or directors of Biophan and own the number of shares set forth in Security Ownership of Certain Beneficial Owners and Management. Except as to these named shareholders, to the best of our knowledge, each of these shareholders will own less than 1% of our outstanding shares following completion of this offering and the sale of the shares registered hereunder.

SELLING SHAREHOLDERS

Name of Shareholder	Position, Office or Material Relationship	Securities Held Before Offering		Amount Offered		Amount % after Offering Complete
		Common Shares	Warrant Shares	Common Shares	Warrant Shares	
Spectrum	None	0	0	8,960,000	0	0/0
Carolina Financial	None	0	0	0	488,000	0/0
William Prather	Financial Advisor	0	12,500	0	12,500	0/0
Robert Cascella	Financial Advisor	0	36,358	0	36,358	0/0
Michael Niedswiecki	Financial Advisor	0	36,357	0	36,357	0/0
Michael Mascia	Financial Advisor	0	36,357	0	36,357	0/0
Westbay Biomed Solutions, LLC	Greater than 10% Shareholder	662,857	1,180,000	0	1,180,000	662,857/1.5%
Private Placement Shareholders						
Bryan, Jennifer	None	25,000	12,500	25,000	12,500	0/0
Buchholz, Rick	None	50,000	25,000	50,000	25,000	0/0
Erhart, Joseph	None	20,000	10,000	20,000	10,000	0/0
Kahle, Ronald, Jr.	None	100,000	50,000	100,000	50,000	0/0
Kahle, Terry	None	20,000	10,000	20,000	10,000	0/0
Knueve, Michael	None	20,000	10,000	20,000	10,000	0/0
Knueve, Ronald	None	20,000	10,000	20,000	10,000	0/0
Nienberg, Stephen	None	40,000	20,000	40,000	20,000	0/0
Recker, Greg	None	20,000	10,000	20,000	10,000	0/0
Unverferth, Brad	None	285,000	142,500	285,000	142,500	0/0
Askins, Randall	None	20,000	10,000	20,000	10,000	0/0
Averesch, Michael	None	100,000	50,000	100,000	50,000	0/0
Erhart, Brian	None	30,000	15,000	30,000	15,000	0/0
Gerding, William and Debra	None	40,000	20,000	40,000	20,000	0/0
Hortstman, Dennis	None	40,000	20,000	40,000	20,000	0/0
Unverferth, Jason	None	60,000	30,000	60,000	30,000	0/0
Unverferth, Mel and Beverly	None	40,000	20,000	40,000	20,000	0/0
Bilski, Dianna	None	35,800	17,900	35,800	17,900	0/0
Cleary, Brian	None	20,000	10,000	20,000	10,000	0/0
Fortman, Gary J. and Deters, Jeffrey R.	None	20,000	10,000	20,000	10,000	0/0
Fortman, Gary J.	None	40,000	20,000	40,000	20,000	0/0
Hoellrich, Anthony J.	None	20,000	10,000	20,000	10,000	0/0
Hoellrich, Daniel L.	None	20,000	10,000	20,000	10,000	0/0
Hoellrich, Douglas D.	None	20,000	10,000	20,000	10,000	0/0
Kahle, Terry L.	None	18,000	9,000	18,000	9,000	0/0
Kahle, Scott L.	None	20,000	10,000	20,000	10,000	0/0
Klass, Terry	None	32,000	16,000	32,000	16,000	0/0
Krontz, Gerald E.						

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

and Cherylanne	None	20,000	10,000	20,000	10,000	0/0
Maag, Phillip D.	None	40,000	20,000	40,000	20,000	0/0
Sarka, Robert J.	None	50,000	25,000	50,000	25,000	0/0
Asad, Susan Sutherland	None	14,000	7,000	14,000	7,000	0/0
Berger, Charles W., Jr.	None	20,000	10,000	20,000	10,000	0/0
Brown, Meagan	None	20,000	10,000	20,000	10,000	0/0
Brown, Grayling	None	16,000	8,000	16,000	8,000	0/0
Bruskotter, Dennis	None	20,000	10,000	20,000	10,000	0/0
Deters, Jeffrey	None	40,000	20,000	40,000	20,000	0/0
Donnelly, Michael	None	20,000	10,000	20,000	10,000	0/0
Fortman, Christopher & Craig	None	20,000	10,000	20,000	10,000	0/0
Fortman, Karl & Judy	None	20,000	10,000	20,000	10,000	0/0
Gabor, Constance	None	80,000	40,000	80,000	40,000	0/0
Gudewicz, Patrice	None	10,000	5,000	10,000	5,000	0/0
Gudewicz, Richard	None	20,000	10,000	20,000	10,000	0/0
Hohlbein, Michael	None	50,000	25,000	50,000	25,000	0/0
Knueve, Ronald & Bonnie	None	10,000	5,000	10,000	5,000	0/0
Kreinbrink, John	None	20,000	10,000	20,000	10,000	0/0
Otto, Jon & Karen	None	20,000	10,000	20,000	10,000	0/0
Rosengarten, Kurt	None	20,000	10,000	20,000	10,000	0/0
Schimmoeller, Craig & Brenda	None	100,000	50,000	100,000	50,000	0/0
Schroeder, Randal & Pamela	None	20,000	10,000	20,000	10,000	0/0
Scodellaro, James	None	10,000	5,000	10,000	5,000	0/0
Siefker, Greg	None	20,000	10,000	20,000	10,000	0/0
Steffey, Billie & Rita	None	10,000	5,000	10,000	5,000	0/0
Strauer, Robert	None	10,000	5,000	10,000	5,000	0/0
Utrup, Kurt	None	10,000	5,000	10,000	5,000	0/0
Vorst, Steven	None	150,000	75,000	150,000	75,000	0/0
Warnecke, Rick	None	100,000	50,000	100,000	50,000	0/0
Winkle, Roger	None	40,000	20,000	40,000	20,000	0/0
Wittlinger, Mona	None	6,000	3,000	6,000	3,000	0/0
Anstadt, George & Nancy	None	100,000	50,000	100,000	50,000	0/0
Averesch, Michael	None	120,000	60,000	120,000	60,000	0/0
Bachmann, Roberta	None	20,000	10,000	20,000	10,000	0/0
Barnes, Alvin	None	40,000	20,000	40,000	20,000	0/0
Brashear, Robert	None	17,000	8,500	17,000	8,500	0/0
Bowman, Donald	None	10,000	5,000	10,000	5,000	0/0
Glendale Investments, Ltd.	None	120,000	60,000	120,000	60,000	0/0
Butler, Daniel & Sue	None	20,000	10,000	20,000	10,000	0/0
Cleary, Michael	None	10,000	5,000	10,000	5,000	0/0
Conditioning Concepts	None	20,000	10,000	20,000	10,000	0/0
DeKalb, Daryl	None	118,500	59,250	118,500	59,250	0/0
Dirty Dozen Investing	None	45,000	22,500	45,000	22,500	0/0
Eisler, Craig	None	16,000	8,000	16,000	8,000	0/0
Ellerbrock, Daniel & Carol	None	20,000	10,000	20,000	10,000	0/0
Estlack, Fred	None	16,000	8,000	16,000	8,000	0/0
Fortman, Douglas	None	30,000	15,000	30,000	15,000	0/0
Garman, Richard	None	80,000	40,000	80,000	40,000	0/0
General Medina Development	None	11,400	5,700	11,400	5,700	0/0
Grenot, Michael	None	50,400	25,200	50,400	25,200	0/0
Helfer, Jeffrey L.	Vice President	100,000	50,000	100,000	50,000	0/0
Jaensch, Guenter	Chairman of the Board					

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

& Terri		300,000	150,000	300,000	150,000	0/0
Jeary, Richard	None	10,000	5,000	10,000	5,000	0/0
Kahle, Carl	None	20,000	10,000	20,000	10,000	0/0
Kahle, Gary	None	40,000	20,000	40,000	20,000	0/0
Kahle, Ronald	None	50,000	25,000	50,000	25,000	0/0
Kahle, Timothy M.	None	10,000	5,000	10,000	5,000	0/0
Kahle, Timothy R.	None	20,000	10,000	20,000	10,000	0/0
Kenzie, Allan & Bette	None	100,000	50,000	100,000	50,000	0/0
Knueve, Dan	None	20,000	10,000	20,000	10,000	0/0
Knueve, Ed	None	20,000	10,000	20,000	10,000	0/0
Knueve, Ronald & Bonnie	None	10,000	5,000	10,000	5,000	0/0
Lippco Capital LLC	None	50,000	25,000	50,000	25,000	0/0
MacDonald, Vice President Stuart		60,000	30,000	60,000	30,000	0/0
Mahley, Mary	None	100,000	50,000	100,000	50,000	0/0
Mahley, Stephen	None	100,000	50,000	100,000	50,000	0/0
Masters, Vernon	None	40,000	20,000	40,000	20,000	0/0
Moore, Dennis	None	12,000	6,000	12,000	6,000	0/0
Nelson, Laura M.	None	20,000	10,000	20,000	10,000	0/0
Neu, Julie	None	10,000	5,000	10,000	5,000	0/0
Newman, Reginald	None	50,000	25,000	50,000	25,000	0/0
Nowak, Ronald	None	16,000	8,000	16,000	8,000	0/0
Pierce, Frederick	None	40,000	20,000	40,000	20,000	0/0
Sarka, Robert	None	32,000	16,000	32,000	16,000	0/0
Sarka, Robert & Karen	None	50,000	25,000	50,000	25,000	0/0
Schimmoeeller Family Rev. Living Trust	None	20,000	10,000	20,000	10,000	0/0
Siefker, Joseph & Doris	None	20,000	10,000	20,000	10,000	0/0
Siefker, Thomas	None	20,000	10,000	20,000	10,000	0/0
Slawson, Kenneth	None	51,000	25,500	51,000	25,500	0/0
Smith, Steven & Mary	None	20,000	10,000	20,000	10,000	0/0
Terens, Frederick	None	16,000	8,000	16,000	8,000	0/0
Unverferth, Jeffrey	None	46,000	23,000	46,000	23,000	0/0
von der Embse, Barry	None	60,000	30,000	60,000	30,000	0/0
Warnecke, Kevin & Michelle	None	20,000	10,000	20,000	10,000	0/0
Western Harbor Association	None	40,000	20,000	40,000	20,000	0/0
Wittlinger, David	None	664,000	332,000	664,000	332,000	0/0
Wittlinger, Donna	None	12,000	6,000	12,000	6,000	0/0
Wittlinger, Mona	None	26,000	13,000	26,000	13,000	0/0
Wittlinger, Viola	None	80,000	40,000	80,000	40,000	0/0
Wittlinger, Walter	None	40,000	20,000	40,000	20,000	0/0
Wood, Robert J. Vice President/CFO		60,000	30,000	60,000	30,000	0/0

PLAN OF DISTRIBUTION

General

Spectrum is offering the common shares for its account as statutory underwriter, and not for our account. We will not receive any proceeds from the sale of common shares by Spectrum. Spectrum may offer for sale up to 8,960,000 common shares which it may acquire pursuant to the terms of the common stock purchase agreement. Spectrum is a statutory underwriter within the meaning of the Securities Act of 1933 in connection with such sales of common shares and will be acting as an underwriter in its resales of the

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

common shares under this prospectus. Spectrum has, prior to any sales, agreed that its trading activities in our securities will comply with applicable state and federal securities laws, rules and regulations and the rules and regulations. We will pay the costs of registering the shares under this prospectus, including legal fees.

To permit Spectrum to resell the common shares issued to it under the common stock purchase agreement, we agreed to register those shares and to maintain that registration. To that end, we have agreed with Spectrum that we will prepare and file such amendments and supplements to the registration statement and the prospectus as may be necessary in accordance with the

Page

64

Securities Act of 1933 and the rules and regulations promulgated thereunder, to keep it effective until the earliest of any of the following dates:

- * the date after which all of the common shares held by Spectrum that are covered by the registration statement have been sold by Spectrum pursuant to such registration statement;
- * the date after which all of the common shares held by Spectrum that are covered by the registration statement may be sold, in the opinion of our counsel, without restriction under the Securities Act of 1933; or
- * the date after which all of the common shares held by Spectrum that are covered by the registration statement may be sold pursuant to Rule 144(k) under the Securities Act of 1933, without limitation as to time, manner of sale or volume.

Shares of common stock offered through this prospectus may be sold from time to time by Spectrum or the other selling shareholders; or by pledgees, donees, transferees or other successors in interest to such other selling shareholders. We will supplement this prospectus to disclose the names of any pledgees, donees, transferees, or other successors in interest to such shareholders (other than Spectrum) that intend to offer common stock through this prospectus.

Sales may be made on the OTC.BB or otherwise at prices and at terms then prevailing or at prices related to the then current market price, or in negotiated private transactions, or in a combination of these methods. Each selling shareholder will act independently of us in making decisions with respect to the form, timing, manner and size of each sale. We have been informed by Spectrum and Carolina that there are no existing arrangements between it and any other stockholder, broker, dealer, underwriter or agent relating to the distribution of this prospectus. Spectrum is an underwriter in connection with resales of its shares.

The common shares may be sold in one or more of the following manners:

- * a block trade in which the broker or dealer so engaged will attempt to sell the shares as agent, but may position and resell a portion of the block as principal to facilitate the transaction;
- * ordinary brokerage transactions and transactions in which the broker solicits purchases; or
- * privately negotiated transactions as permitted by Rule 15a-6 under the Exchange Act of 1934.

In effecting sales hereunder, Spectrum or other selling shareholders may arrange for other brokers or dealers to participate. Except as disclosed in a

supplement to this prospectus, no broker-dealer will be paid more than a customary brokerage commission in connection with any sale of the common shares by Spectrum. Brokers or dealers may receive commissions, discounts or other concessions from the selling stockholders in amounts to be negotiated immediately prior to the sale. The compensation to a particular broker-dealer may be in excess of customary commissions. Profits on any resale of the common shares as a principal by such broker-dealers and any commissions

Page

65

received by such broker-dealers may be deemed to be underwriting discounts and commissions under the Securities Act. Any broker-dealer participating in such transactions as agent may receive commissions from the selling shareholder, and, if they act as agent for the purchaser of such common shares, from such purchaser.

In addition, any common shares covered by this prospectus which qualify for sale pursuant to Rule 144 may be sold under Rule 144 rather than pursuant to this prospectus.

However, since Spectrum is an underwriter, Rule 144 of the Securities Act of 1933 is not available to Spectrum to sell its shares.

We will not receive any of the proceeds from the sale of these common shares, although we have paid the expenses of preparing this prospectus and the related registration statement of which it is a part.

Spectrum is subject to the applicable provisions of the Exchange Act of 1934, including without limitation, Rule 10b-5 and Regulation M thereunder. Under applicable rules and regulations under the Exchange Act of 1934, any person engaged in a distribution of the common shares may not simultaneously purchase such securities for a period beginning when such person becomes a distribution participant and ending upon such person's completion of participation in a distribution. In addition, in connection with the transactions in the common shares, Spectrum will be subject to applicable provisions of the Exchange Act of 1934 and the rules and regulations under that Act, including, without limitation, the rules set forth above. These restrictions may affect the marketability of the common shares.

Each selling shareholder will pay all commissions and their own expenses, if any, associated with the sale of the common shares, other than the expenses associated with preparing this prospectus and the registration statement of which it is a part.

Underwriting Compensation and Expenses

The underwriting compensation for Spectrum will depend on the amount of financing that we are able to obtain under the common stock purchase agreement, up to a maximum of approximately \$ 600,000 if we are able to obtain the entire \$3,000,000 in financing. Spectrum will purchase shares under the common stock purchase agreement at a price equal to 80% of the volume weighted average daily price of our common stock on the OTC.BB, as reported by Bloomberg Financial L.P. for each day in the pricing period with respect to each draw down request.

In addition, we are obligated to pay Carolina, as compensation for its services as placement agent, a cash fee equal to 10% of the gross proceeds received from Spectrum under the common stock purchase agreement for draw downs under the equity line. The placement agent compensation to Carolina will depend on the amount of financing that we are able to obtain under the common stock purchase agreement, up to a maximum of \$300,000 if we are able to obtain the entire \$3,000,000 in financing. We also agreed to issue to

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

Carolina warrants to purchase up to 480,010 shares of our common stock at an exercise price equal to 110% of the per share purchase price, as calculated under the Stock Purchase Agreement, on the date of issuance. The warrant will expire five years from the date of issuance.

LEGAL MATTERS

The validity of the common stock offered hereby will be passed upon for Biophan by Boylan, Brown, Code, Vigdor & Wilson, LLP, Rochester, New York. The firm has been granted options to purchase 40,000 shares of Biophan's

Page

66

common stock at \$.50 per share in connection with services rendered prior to the commencement of this offering, and warrants to purchase an additional 161,290 shares at \$.31 per share as partial consideration for its work in connection with this offering.

EXPERTS

The financial statements of Biophan as of and for the years ended February 28, 2003 and 2002, appearing in this prospectus have been audited by Goldstein Golub Kessler LLP, Certified Public Accountants, as set forth in their report thereon appearing elsewhere herein, and are included in reliance upon such reports given upon the authority of such firm as experts in accounting and auditing.

WHERE YOU CAN FIND ADDITIONAL INFORMATION

Biophan files current, quarterly and annual reports with the SEC on forms 8-KSB, 10QSB and 10KSB. Biophan has filed with the SEC a registration statement on Form SB-2 (together with all amendments and exhibits thereto, under the Securities Act, with respect to the shares being offered in this offering. This prospectus does not contain all of the information set forth in the registration statement, certain items of which are omitted in accordance with the rules and regulations of the SEC. The omitted information may be inspected and copied at the Public Reference Room maintained by the SEC at Judiciary Plaza, 450 Fifth Street, N.W., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC at <http://www.sec.gov>. Copies of such material can be obtained from the public reference section of the SEC prescribed rates. Statements contained in this prospectus as to the contents of any contract or other document filed as an exhibit to the registration statement are not necessarily complete and in each instance reference is made to the copy of the document filed as an exhibit to the registration statement, each statement made in this prospectus relating to such documents being qualified in all respect by such reference.

For further information with respect to Biophan and the securities being offered hereby, reference is hereby made to such registration statement, including the exhibits thereto and the financial statements, notes, and schedules filed as a part thereof.

Page

67

FINANCIAL STATEMENTS

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

BIOPHAN TECHNOLOGIES, INC.
AND SUBSIDIARIES
(A Development Stage Company)

CONSOLIDATED FINANCIAL STATEMENTS

FEBRUARY 28, 2003

BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES
(A Development Stage Company)

CONTENTS
FEBRUARY 28, 2003

Independent Auditor's Report	F-1
Consolidated Financial Statements:	
Balance Sheet	F-2
Statement of Operations	F-3
Statement of Stockholders' Deficiency	F-4
Statement of Cash Flows	F-5
Notes to Consolidated Financial Statements	F-6 - F-7

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors
Biophan Technologies, Inc.

We have audited the accompanying consolidated balance sheet of Biophan Technologies, Inc. and Subsidiaries (a development stage company) as of February 28, 2003, and the related consolidated statements of operations, stockholders' deficiency, and cash flows for each of the two years in the period then ended, and the amounts in the cumulative column in the consolidated statements of operations, stockholders' deficiency, and cash flows for the period from August 1, 1968 (date of inception) to February 28, 2003. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Biophan Technologies, Inc. and Subsidiaries as of February 28, 2003 and the results of

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

their operations and their cash flows for each of the two years in the period then ended and the amounts included in the cumulative column in the consolidated statements of operations and cash flows for the period from August 1, 1968 to February 28, 2003 in conformity with accounting principles generally accepted in the United States of America.

/s/GOLDSTEIN GOLUB KESSLER LLP
New York, New York

April 10, 2003

Pg. F-1

BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES
(A Development Stage Company)

CONSOLIDATED BALANCE SHEET

February 28, 2003

ASSETS

Current assets:

Cash	\$ 48,935
Investments in marketable securities	302,000
Advances receivable	10,127
Due from related party	24,368
Prepaid expenses	90,923

Total current assets	476,353
----------------------	---------

Fixed assets - at cost, net	63,232
-----------------------------	--------

Other assets:

Intellectual property rights	70,000
Security deposit	2,933
Deferred equity placement costs	70,538
Deferred tax asset, net of valuation allowance of \$2,120,000	-

143,471

\$ 683,056

LIABILITIES AND STOCKHOLDERS' DEFICIENCY

Current liabilities:

Accounts payable and accrued expenses	\$ 343,216
Loan payable to stockholder	143,570
Payable to related party	300,000
Due to related party	9,401

Total current liabilities	796,187
---------------------------	---------

Long-term payable to related party, less discount	83,333
---	--------

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

Stockholders' deficiency:

Common stock - \$.005 par value:	
Authorized, 60,000,000 shares	
Issued and outstanding, 37,634,693 shares	188,173
Additional paid-in capital	7,588,520
Deficit accumulated during the development stage	(7,973,157)

	(196,464)

	\$ 683,056
	=====

See notes to consolidated financial statements

Pg. F-2

BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES
(A Development Stage Company)

CONSOLIDATED STATEMENT OF OPERATIONS

	Year ended February 28, 2003	Year ended February 28, 2002	Period from August 1, 1968 (date of inception) to February 28, 2003
Operating expenses:			
Salaries and related	\$ 648,304	\$ 461,629	\$ 1,169,794
Research and development	1,373,124	949,124	2,435,292
Professional fees	522,115	1,310,916	1,871,716
Write-down of intellectual property rights	40,000		530,000
General and administrative	582,174	475,520	1,084,254
	-----	-----	-----
Operating loss	(3,165,717)	(3,197,189)	(7,091,156)
	-----	-----	-----
Other income (expense):			
Interest expense	(447,853)	(540,543)	(1,001,396)
Interest income	17,083	26,061	44,763
Other income	187,040	42,035	229,075
Other expense	(28,805)	(36,281)	(65,086)
	-----	-----	-----
Total other expenses, net	(272,535)	(508,728)	(792,644)
	-----	-----	-----
Loss from continuing operations	(3,438,252)	(3,705,917)	(7,883,800)
Loss from discontinued operations			(89,357)
	-----	-----	-----

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

Net loss	\$ (3,438,252)	\$ (3,705,917)	\$ (7,973,157)
Loss per common share - basic and diluted	\$ (0.11)	\$ (0.14)	
Weighted average shares outstanding	31,731,051	27,000,962	

See notes to consolidated financial statements

Pg. F-3

BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES
(A Development Stage Company)

CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIENCY

Period from August 1, 1968 (date of inception) to February 28, 2003

	Number of Shares	Common Stock	Additional Paid-in Capital	Deficit Accumulated During the Development Stage	Stockholders' Equity (Deficiency)
1969 - 14,130 shares issued for services for \$.05 per share	14,130	\$ 70	\$ 637		\$ 707
1970 - 1,405,000 shares issued for mining rights for \$.05 per share	1,405,000	7,025	63,225		70,250
1970 - 55,500 shares issued for services for \$.05 per share	55,500	278	2,497		2,775
1973 - 10,000 shares issued for services for \$.05 per share	10,000	50	450		500
1976 - 500 shares issued for services for \$.05 per share	500	3	22		25
1978 - 12,000 shares issued for services for \$.05 per share	12,000	60	540		600
1980 - 225,000 shares issued for services for \$.05 per share	225,000	1,125	10,125		11,250
1984 - 20,000 shares issued for services for \$.05 per share	20,000	100	900		1,000
1986 - 10,000 shares issued for services for \$.05 per share					

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

	10,000	50	450		500
1990 - 10,000 shares issued for services for \$.05 per share	10,000	50	450		500
1993 - 25,000 shares issued for services for \$.05 per share	25,000	125	1,125		1,250
Net loss from inception through February 28, 1998				(89,357)	(89,357)

Balance at February 28, 1998	1,787,130	8,936	80,421	(89,357)	-
1999 - 10,000 shares issued for services for \$.05 per share	10,000	50	450	\$	500
1999 - 1,000,000 shares issued for services for \$.005 per share	1,000,000	5,000			5,000
Net loss for the year ended February 28, 1999				(5,500)	(5,500)

Balance at February 28, 1999	2,797,130	13,986	80,871	(94,857)	-
2000 - 1,000,200 shares issued for services for \$.005 per share	1,000,200	5,001			5,001

See notes to consolidated financial statements

Pg. F-4

BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES
(A Development Stage Company)

CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIENCY

Period from August 1, 1968 (date of inception) to February 28, 2003

	Number of Shares	Common Stock	Additional Paid-in Capital	Deficit Accumulated During the Development Stage	Stockholders' Equity (Deficiency)
Net loss for the year ended February 29, 2000				(5,001)	(5,001)

Balance at February 29, 2000	3,797,330	18,987	80,871	(99,858)	-

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

2000 - 250,000 shares issued for services for \$.005 per share	250,000	1,250			1,250
2000 - Expenses paid by stockholder			2,640		2,640
2000 - 10,759,101 shares issued for acquisition of Antisense Technology, Inc.	10,759,101	53,795	121,205		175,000
2000 - 10,759,101 shares issued for cash for \$.005 per share	10,759,101	53,796	121,204		175,000
Net loss for the year ended February 28, 2001				(729,130)	(729,130)

Balance at February 28, 2001	25,565,532	127,828	325,920	(828,988)	(375,240)
2001 - 2,399,750 shares issued for cash for \$1.00 per share	2,399,750	11,999	2,387,751		2,399,750
2001 - 468,823 shares issued for interest	468,823	2,344	466,479		468,823
2001 - Redemption of 200,000 shares	(200,000)	(1,000)			(1,000)
2001 - 1,315,334 shares issued upon conversion of bridge loans at \$.75 per share	1,315,334	6,576	979,924		986,500
2001 - Offering costs associated with share issuances for cash			(254,467)		(254,467)
2002 - Grant of stock options for services			702,800		702,800
Net loss for the year ended February 28, 2002				(3,705,917)	(3,705,917)

Balance at February 28, 2002	29,549,439	147,747	4,608,407	(4,534,905)	221,249
2002 - Shares issued for cash for \$.34 per share	993,886	4,969	337,461		342,430
2002 - Shares issued for cash for \$.15 per share	1,192,874	5,964	167,002		172,966
2002 to 2003 - Shares issued for cash for \$.25 per share	5,541,100	27,706	1,357,569		1,385,275
2002 to 2003 - Shares issued as commissions on offerings	357,394	1,787	(1,787)		-
2002 to 2003 Cash commissions on offerings			(119,488)		(119,488)
Offering costs			(45,644)		(45,644)
Grant of stock options for services			485,000		485,000
Intrinsic value of beneficial conversion feature of note payable and MRI liability			800,000		800,000
Net loss for the year ended February 28, 2003				(3,438,252)	(3,438,252)

Balance at February 28, 2003	37,634,693	\$ 188,173	\$7,588,520	\$(7,973,157)	\$(196,464)
=====					

See notes to consolidated financial statements

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

Pg. F-5

BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES
(A Development Stage Company)

CONSOLIDATED STATEMENT OF CASH FLOWS

	Year ended February 28, 2003	Year ended February 28, 2002	Period from August 1, 1968 inception) to February 28, 2003
Cash flows from operating activities:			
Net loss	\$ (3,438,252)	\$ (3,705,917)	\$ (7,973,157)
Adjustments to reconcile net loss to net cash used in operating activities:			
Depreciation	25,601	14,762	40,530
Realized and unrealized losses on marketable securities	28,805	38,143	66,948
Amortization of interest on convertible notes payable	383,333	-	383,333
Write-down of intellectual property rights	40,000	-	530,000
Amortization of discount on payable to related party	-	62,000	75,000
Issuance of common stock for services	-	-	101,108
Issuance of common stock for interest	-	468,823	468,823
Grant of stock options for services	485,000	702,800	1,187,800
Expenses paid by stockholder	-	-	2,640
Changes in operating assets and liabilities:			
Increase in advances receivable	(10,127)	-	(10,127)
Increase in due from related parties	(24,368)	-	(24,368)
(Increase) decrease in prepaid expenses	896	(91,819)	(90,923)
Increase in security deposits	-	(2,933)	(2,933)
Increase in accounts payable and accrued expenses	214,176	18,184	329,885
Decrease in due to related parties	(6,948)	(153,787)	(34,095)
Net cash used in operating activities	(2,301,884)	(2,649,744)	(4,949,536)
Cash flows from investing activities:			
Purchases of fixed assets	(7,951)	(90,811)	(103,762)
Sales of marketable securities	540,000	377,270	917,270
Purchases of marketable securities	(302,000)	(984,218)	(1,286,218)
Net cash provided by (used in) investing activities	230,049	(697,759)	(472,710)
Cash flow from financing activities:			
Proceeds of bridge loans	-	986,500	986,500
Loan from stockholder	143,570	-	143,570
Line of credit borrowing from related party	300,000	-	300,000
Net proceeds from sales of capital stock	1,735,539	2,201,110	4,111,649
Deferred equity placement costs	(70,538)	-	(70,538)
Net cash provided by financing activities	2,108,571	3,187,610	5,471,181

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

Net increase (decrease) in cash and cash equivalents	36,736	(159,893)	48,935
Cash and cash equivalents at beginning of period	12,199	172,092	-
Cash and cash equivalents at end of period	\$ 48,935	\$ 12,199	\$ 48,935

Supplemental schedule of noncash investing and financing activities:

Intellectual property acquired through issuance of common stock and assumption of related party payable		\$	175,000
Acquisition of intellectual property rights		\$	425,000
Issuance of common stock upon conversion of bridge loans	\$ 986,500	\$	986,500

See notes to consolidated financial statements

Pg. F-6

BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES
(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
February 28, 2003

1. PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

The consolidated financial statements include the accounts of Biophan Technologies, Inc. ("Biophan") and its wholly owned subsidiaries, LTR Antisense Technology, Inc. ("Antisense") and MRIC Drug Delivery Systems, LLC ("MRIC") (collectively referred to as the "Company"). All significant intercompany accounts and transactions have been eliminated in consolidation.

The Company is in the development stage and is expected to remain so for at least the next 12 months. The Company is developing technologies that make biomedical devices safe for use in an MRI (Magnetic Resonance Imaging) machine.

The Company was incorporated under the laws of the State of Idaho on August 1, 1968. On January 12, 2000, the Company changed its domicile to Nevada by merging into a Nevada corporation, and on July 19, 2001, changed its name to Biophan Technologies, Inc.

The Company has not generated any revenue throughout its history. The Company's ability to continue in business is dependent upon obtaining sufficient financing or attaining future profitable operations.

On December 1, 2000, the Company acquired LTR Antisense Technology, Inc., a New York corporation ("LTR"), from Biomed Solutions, LLC (formerly Biophan,

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

LLC), a New York limited liability company ("Biomed"), in a share for share exchange. As a result of the exchange, LTR became a wholly owned subsidiary of the Company. The exchange was consummated pursuant to and in accordance with an Exchange Agreement, originally dated December 1, 2000 and subsequently amended, by and among the Company, LTR and Biomed. LTR owns multiple patents for proprietary HIV antisense gene therapy technology.

In connection with the exchange, the Company (i) issued an aggregate of 10,759,101 shares of common stock to Biomed in exchange for all the issued shares of LTR and (ii) issued an aggregate of 10,759,101 shares of common stock to a group of investors for \$175,000. Also on December 1, 2000, the Company acquired intellectual property rights, including a pending patent to the MRI-compatible pacemaker technology from Biomed (the "Assignment"), for future consideration of \$500,000 ("MRI technology purchase liability payable") The Assignment was consummated pursuant to, and in accordance with, an Assignment and Security Agreement, originally dated December 1, 2000 and subsequently amended, by and between the Company and Biomed.

Pg. F-

BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES
(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
February 28, 2003

For purposes of the statement of cash flows, the Company considers all highly liquid instruments with an original maturity of three months or less to be cash equivalents.

The Company maintains cash in bank deposit accounts which, at times, exceed federally insured limits. The Company has not experienced any losses on these accounts.

Marketable securities that are bought and held principally for the purpose of selling them in the near term are classified as trading securities. Trading securities are recorded at fair value, with the change in fair value during the period included in operations.

Depreciation of fixed assets is provided by the straight-line method over the estimated useful lives of the related assets. Amortization of acquired intellectual property rights is provided by the straight-line method over 17 years. Costs for internally developed intellectual property rights with indeterminate lives are expensed as incurred.

At each balance sheet date, the Company evaluates the period of amortization of intangible assets. The factors used in evaluating the period of amortization include: (i) current operating results, (ii) projected future operating results, and (iii) any other material factors that affect continuity of the business.

Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates expected to apply when the differences are expected to be realized. A valuation allowance is recognized if it is anticipated that some or all of the deferred tax asset may not be realized.

Basic loss per common share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period.

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

Diluted loss per common share gives effect to dilutive options, warrants and other potential common stock outstanding during the period. Potential common stock has not been included in the computation of diluted loss per share, as the effect would be antidilutive.

The Company has elected to apply Accounting Principles Board ("APB") Opinion No. 25, Accounting for Stock Issued to Employees, and related interpretations in accounting for its stock options issued to employees (intrinsic value) and has adopted the disclosure-only provisions of Statement of Financial Accounting Standards ("SFAS") No. 123, Accounting for Stock-Based Compensation. Had the Company elected to recognize compensation cost based on the fair value of the options granted at the grant date as prescribed by SFAS No. 123, the Company's net loss and loss per common share would have been as follows:

Year ended February 28,	2003	2002
-----	-----	-----
Net loss - as reported	\$3,438,252	\$3,705,917
 Add: Stock-based employee compensation Expense included in reported net loss, net of related tax effects	 458,000	 268,000
 Deduct: Total stock-based employee compensation expense determined under fair value based method for all awards, net of related tax effects	 524,000	 280,000
-----	-----	-----
Net loss - pro forma	\$3,372,252	\$3,693,917
=====	=====	=====
Basic and diluted loss per share - as reported	\$.11	\$.14
=====	=====	=====
Basic and diluted loss per share - pro forma	\$.11	\$.14
=====	=====	=====

The Company's assumptions used to calculate the fair values of options issued during the year ended February 28, 2003 were (i) risk-free interest rates of 3.05% through 4.75%, (ii) expected lives of 5 to 10 years, (iii) expected volatility of 90%, and (iv) expected dividends of zero.

The Company's assumptions used to calculate the fair values of options issued during the year ended February 28, 2002 were (i) risk-free interest rates of 4.27% and 4.87%, (ii) expected life of nine years, (iii) expected volatility of 90.%, and (iv) expected dividends of zero.

The preparation of financial statements in conformity with generally accepted accounting principles requires the use of estimates by management. Actual results could differ from these estimates.

Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the accompanying financial statements.

Pg. F-

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
February 28, 2003

2. INVESTMENTS IN MARKETABLE SECURITIES:

Investments in trading securities are summarized as follows at February 28, 2003:

	Cost	Gross Unrealized Gain/Loss	Fair Value
Corporate debt securities	\$302,000	\$ -	\$302,000

There were no unrealized holding losses on trading securities for the year ended February 28, 2003.

3. PREPAID EXPENSES:

Prepaid expenses at February 28, 2003 consist of the following:

Prepaid consulting fees	\$ 53,933
Prepaid insurance	18,865
Prepaid supplies	18,125

	\$ 90,923
	=====

4. FIXED ASSETS:

Fixed assets, at cost, consist of the following:

		Depreciation/ Amortization Period
Furniture & Equipment	\$39,320	5-7 years
Computers	10,283	5 years
Internet Web site	54,159	7 years

	103,762	
Less accumulated depreciation	(40,530)	

	\$63,232	
	=====	

Depreciation expense for the years ended February 28, 2003 and 2002 amounted to \$25,601 and \$14,762, respectively. Depreciation expense for the period from August 1, 1968 (Date of Inception) to February 28, 2003 was \$40,530.

5. INTELLECTUAL PROPERTY RIGHTS:

Intellectual property rights were acquired on December 1, 2000 and encompass two areas: (1) The utilization of new proprietary technology to prevent implantable cardiac pacemakers and other critical and life-sustaining medical devices from being affected by MRI and other equipment using magnetic fields, radio waves and similar forms of electromagnetic interference ("EMI"), and (2)

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

the use of proprietary antisense gene therapy technology to inhibit the spread of human immunodeficiency virus (HIV-1) infection in conjunction with the use of lentiviral vectors. In the current year ended February 28, 2003, the stated cost value of the gene technology rights in the amount of \$40,000 was written off. The Company has discontinued its development efforts in this area.

6. LOAN AGREEMENTS:

In June 2002, the Company signed a Loan Agreement with a shareholder providing for borrowings of up to \$400,000 with interest payable at 8% per annum. Principal and accrued interest become due and payable on December 31, 2003. At February 28, 2003, \$143,570 had been borrowed under this Agreement.

In June 2002, the Company executed a line-of-credit agreement (the "Line") with Biomed that provided for borrowings up to \$250,000. Interest accrues at 8% per annum. Upon execution of the Line, Biomed received warrants to purchase 325,000 shares of restricted common stock at \$1.00 per share. The warrants were valued at approximately \$234,000 which was recorded as a discount against the Convertible Promissory Note (the "Note") supporting the Line. At issuance, the Note was convertible into shares of the Company's common stock, at a price below the market value of such stock. The intrinsic value of the beneficial conversion feature of the Note was recorded as an additional discount, such that the full \$250,000 issued was discounted, with a corresponding increase to additional paid-in capital.

On August 19, 2002, the Line was increased by \$100,000 and the expiration date thereof was extended to August 19, 2003. The payment date of amounts borrowed under the original Line was extended to December 1, 2002. In consideration for the increase in the Line, Biomed received 30,000 additional warrants to purchase shares of restricted common stock at a price dependent on the selling price of the Company's stock, as defined. The exercise price of the warrants issued to Biomed in exchange for the increase in the line of credit to \$350,000 and the extension of the payment date to December 1, 2002 is the lowest of (i) the closing bid price on June 4, 2002; (ii) the closing bid price on the date of exercise; or (iii) the lowest per share purchase price paid by any third party between June 4, 2002 and the exercise date. The fair value of the warrants - in accordance with guidance provided by Statement of Financial Accounting Standards No. 123, Accounting for Stock-Based Compensation - was estimated at the date of grant using the Black-Scholes option pricing model with the following assumptions: risk-free interest rate of 5.25; no dividend yield; volatility factor of the expected market price of the company's common stock of 0.0%, and an expected life of 2.8 years. The value attributed to the warrants was insignificant. As a result, these warrants have been allocated no value. The Company has drawn an additional \$50,000 under the Line, which was also fully discounted as a result of the beneficial conversion feature, which was recorded as additional paid-in capital. At February 28, 2003, the Company has borrowed \$300,000 in aggregate under the Line.

Under the Transfer Agreement dated December 1, 2000, the Company incurred a liability ("MRI technology purchase liability payable") of \$500,000 (including interest of \$75,000) to Biomed in connection with the acquisition of the MRI intellectual property rights described in Note 4. Biomed maintains a security interest in the underlying patents until the liability is satisfied. The intellectual property rights will revert to Biomed if the Company does not satisfy the liability by June 1, 2004. The stated liability bears interest at an annual rate of 8%. The balance of the MRI technology purchase liability payable at February 28, 2002 is \$500,000.

At February 28, 2003, the principal amounts of the Company's obligations

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

approximated their estimated fair values based upon current borrowing rates for similar issues.

In December 2002, in consideration for extending the maturity date to June 1, 2004 and for prior extensions, the Company and Biomed agreed to make the \$500,000 MRI technology purchase liability payable to Biomed convertible at Biomed's election into shares of the Company's common stock at a price dependent on the selling price of the Company's stock, as defined, but below market. Consequently, the intrinsic value of the beneficial conversion feature of the liability was recorded as a discount, such that the full \$500,000 was discounted, with a corresponding increase to additional paid-in capital.

7. STOCKHOLDERS' EQUITY:

In July and August 2002, the Company entered into finder's agreements for the sale of restricted common stock to foreign investors pursuant to the exemption from registration provided in Regulation S of the 1933 Securities Act. The Company issued a total of 2,186,760 shares of stock for aggregate net proceeds of \$491,034 under these agreements.

Effective August 22, 2002, the Company entered into a finder's agreement with a domestic consulting firm providing for the sale of restricted shares of common stock pursuant to Regulation D under the Securities Act. The finder receives a cash fee of 10% plus stock. The Company issued a total of 5,541,100 shares of stock for aggregate net proceeds of \$1,244,505.

During November 2002, the Company entered into a Stock Purchase Agreement with an institutional investor whereby the Company agreed to sell up to \$3,000,000 of the Company's common stock. The agreement requires the Company to file with the Securities and Exchange Commission ("SEC") a Registration Statement covering the shares issuable under this agreement. The Company can begin selling shares to the purchaser immediately after the SEC declares the above-mentioned Registration Statement effective. The Company is in the process of filing for registration.

8. COMMITMENTS:

The Company is obligated under an operating lease for office space expiring September 30, 2004. The Company may terminate the lease upon ninety days prior written notice to the landlord. The aggregate minimum future payments under this lease are payable as follows:

Year ending February 28,	
2004	\$ 46,783
2005	25,083

	\$ 71,866
=====	

Rent expense charged to operations under this operating lease aggregated \$51,321 and \$14,667 for the years ended February 28, 2003 and 2002, respectively. Rent expense charged to operations for the period from August 1, 1968 (Date of Inception) to February 28, 2003 was \$65,988.

9. RELATED PARTY TRANSACTIONS:

Biomed and another related party paid expenses on behalf of the Company aggregating \$128,411 and \$253,014 during the years ended February 28, 2003 and

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

2002, respectively, and \$551,561 for the period August 1, 1968 through February 28, 2003. At February 28, 2003, the balance due from a related party is \$24,368 and the balance due to a separate related party is \$9,401. The amounts due from and to the related parties do not bear interest, and the Company expects to collect and repay these respective balances during the next 12 months.

10. STOCK-BASED COMPENSATION PLAN:

The Company has a stock option plan (the "Plan") which provides for the granting of nonqualified or incentive stock options ("ISO") to officers, key employees, non-employee directors and consultants. The Plan authorizes the granting of options to acquire up to 2,500,000 common shares. ISO grants under the Plan are exercisable at the market value of the Company's stock on the date of such grant. Nonqualified option grants under the Plan are exercisable at amounts determined by the board of directors. All options under the Plan are exercisable at times as determined by the board of directors, not to exceed 10 years from the date of grant. Additionally, the Plan provides for the granting of restricted stock to officers and key employees.

The following table summarizes activity in stock options:

	Options	Weighted- average Exercise Price

Outstanding at March 1, 2001	-	-
Granted	1,779,997	\$.51
Forfeited	-	-
Exercised	-	-

Outstanding at February 28, 2002	1,779,997	\$.51
Granted	739,998	.42
Forfeited	30,000	.50
Exercised	-	-

Outstanding at February 28, 2003	2,489,995	\$.48
=====		
Weighted-average fair value of options granted during the year ended February 28, 2003 and 2002, respectively	\$.33	\$.90
=====		

The following table summarizes information about stock options outstanding and exercisable at February 28, 2003:

Options Outstanding		Options Exercisable	
-----	-----	-----	-----
Weighted Average	Weighted-	Weighted-	Weighted-

Edgar Filing: BIOPHAN TECHNOLOGIES INC - Form 424B3

Range of Exercise Price	Number Outstanding	Remaining Contractual Life	Average Exercise Price	Number Exercisable	Average Exercise Price
\$.10 - \$.43	940,000	7.50 years	\$.33	546,666	\$.27
\$.50 - \$1.00	1,549,995	7.64 years	\$.58	1,017,995	\$.62
\$.10 - \$1.00	2,489,995	7.58 years	\$.48	1,564,661	\$.50

Pg. F-12

BIOPHAN TECHNOLOGIES, INC. AND SUBSIDIARIES
(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
February 28, 2003

At February 28, 2003, 10,005 shares of common stock were reserved for future issuance of stock options.

11. INCOME TAXES:

As of February 28, 2003, the Company had net operating loss carryforwards of approximately \$5,706,000 for federal income tax purposes, which expire through 2023.

The reconciliation of income tax computed at the U.S. federal statutory tax rates to income tax expense is as follows:

Year Ended February 28,	2003	2002
Tax benefit at U.S. statutory rates	34 %	34 %
Increase in valuation allowance	(34)%	(34)%
	-0-%	-0-%

Deferred tax asset is comprised of the following:

February 28, 2003	
Net operating loss carryforwards	\$1,940,000
Write-down of intellectual property rights	180,000
Total deferred tax asset	2,120,000
Valuation allowance	(2,120,000)
Net deferred tax asset	\$ -0-